{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:46:45Z","timestamp":1792504005380,"version":"4.5.0"},"reference-count":605,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12072-017-9799-9","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T17:32:35Z","timestamp":1497547955000},"page":"317-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1899,"title":["Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update"],"prefix":"10.1007","volume":"11","author":[{"given":"Masao","family":"Omata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kokudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoghesh K.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Alcantara","family":"Payawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadahisa","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmas Rinaldi A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentius A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino A.","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Kadir","family":"Dokmeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"key":"9799_CR1","unstructured":"World Health Organaization. Cancer. http:\/\/www.who.int\/mediacentre\/factsheets\/fs297\/en\/ . Accessed 16 April 2017"},{"key":"9799_CR2","doi-asserted-by":"crossref","unstructured":"European Association For The Study of the Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908\u2013943","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"9799_CR3","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095\u20132128","journal-title":"Lancet"},{"key":"9799_CR4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12072-010-9165-7","volume":"4","author":"M Omata","year":"2010","unstructured":"Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439\u2013474","journal-title":"Hepatol Int"},{"key":"9799_CR5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924\u2013926","journal-title":"BMJ"},{"key":"9799_CR6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","volume":"336","author":"HJ Sch\u00fcnemann","year":"2008","unstructured":"Sch\u00fcnemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106\u20131110","journal-title":"BMJ"},{"key":"9799_CR7","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortaloty and prevalence worldwide in 2012. http:\/\/globocan.iarc.fr\/Default.aspx\/ . Accessed 16 April 2017"},{"key":"9799_CR8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","volume":"7","author":"JD Yang","year":"2010","unstructured":"Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448\u2013458","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9799_CR9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","volume":"362","author":"CL Lai","year":"2003","unstructured":"Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089\u20132094","journal-title":"Lancet"},{"key":"9799_CR10","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264\u20131273","journal-title":"Gastroenterology"},{"key":"9799_CR11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602333","volume":"92","author":"J Shi","year":"2005","unstructured":"Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607\u2013612","journal-title":"Br J Cancer"},{"key":"9799_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2011.03.006","volume":"15","author":"KA McGlynn","year":"2011","unstructured":"McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223\u2013243","journal-title":"Clin Liver Dis"},{"key":"9799_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/rtph.1994.1025","volume":"19","author":"JE Doe","year":"1994","unstructured":"Doe JE, Paddle GM. The evaluation of carcinogenic risk to humans: occupational exposures in the spraying and application of insecticides. Regul Toxicol Pharmacol 1994;19:297\u2013308","journal-title":"Regul Toxicol Pharmacol"},{"key":"9799_CR14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","volume":"11","author":"CJ Chen","year":"2007","unstructured":"Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007;11:797\u2013816","journal-title":"Clin Liver Dis"},{"key":"9799_CR15","unstructured":"World Health Organaization. Hepatitis B. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ . Accessed 16 April 2017"},{"key":"9799_CR16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/infdis\/jir687","volume":"205","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Kuo SF, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 2012;205:54\u201363","journal-title":"J Infect Dis."},{"key":"9799_CR17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","volume":"142","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140\u20131149","journal-title":"Gastroenterology"},{"key":"9799_CR18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","volume":"57","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441\u2013450","journal-title":"Hepatology"},{"key":"9799_CR19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","volume":"3","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425\u2013433","journal-title":"Hepatol Int"},{"key":"9799_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0033-1345716","volume":"33","author":"CJ Liu","year":"2013","unstructured":"Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to. J Semin Liver Dis 2013;33:97\u2013102","journal-title":"J Semin Liver Dis"},{"key":"9799_CR21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","volume":"118","author":"JH Kao","year":"2000","unstructured":"Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554\u2013559","journal-title":"Gastroenterology"},{"key":"9799_CR22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","volume":"100","author":"HI Yang","year":"2008","unstructured":"Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134\u20131143","journal-title":"J Natl Cancer Inst"},{"key":"9799_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-12-380888-2.00002-9","volume":"108","author":"JH Kao","year":"2010","unstructured":"Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res 2010;108:21\u201372","journal-title":"Adv Cancer Res"},{"key":"9799_CR24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jhep.2003.12.002","volume":"40","author":"CH Chen","year":"2004","unstructured":"Chen CH, Chen YY, Chen GH, Yang SS, Tang HS, Lin HH, et al. Hepatitis B virus transmission and hepatocarcinogenesis: a 9\u00a0year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol 2004;40:653\u2013659","journal-title":"J Hepatol"},{"key":"9799_CR25","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","volume":"101","author":"MH Chang","year":"2009","unstructured":"Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348\u20131355","journal-title":"J Natl Cancer Inst."},{"key":"9799_CR26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","volume":"12","author":"HI Yang","year":"2011","unstructured":"Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACHB): development and validation of a predictive score. Lancet Oncol 2011;12:568\u2013574","journal-title":"Lancet Oncol"},{"key":"9799_CR27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hep.24121","volume":"53","author":"KS Jung","year":"2011","unstructured":"Jung KS, Kim SU, Ahn SH, Park YN, Kim Do Y, Park JY, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53:885\u2013894","journal-title":"Hepatology"},{"key":"9799_CR28","first-page":"1463","volume":"6","author":"DY Kim","year":"2013","unstructured":"Kim DY, Song KJ, Kim SU, Yoo EJ, Park JY, Ahn SH, et al. Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. Oncol Targets Ther 2013;6:1463\u20131469","journal-title":"Oncol Targets Ther."},{"key":"9799_CR29","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","volume":"121","author":"WR Kim","year":"2015","unstructured":"Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015;121:3631\u20133638","journal-title":"Cancer"},{"key":"9799_CR30","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537\u20131547","journal-title":"Hepatology"},{"key":"9799_CR31","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/hep.510290604","volume":"29","author":"P Fasani","year":"1999","unstructured":"Fasani P, Sangiovanni A, De Fazio C, Borzio M, Bruno S, Ronchi G, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999;29:1704\u20131707","journal-title":"Hepatology"},{"key":"9799_CR32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","volume":"155","author":"F Donato","year":"2002","unstructured":"Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323\u2013331","journal-title":"Am J Epidemiol"},{"key":"9799_CR33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463\u2013472","journal-title":"Gastroenterology"},{"key":"9799_CR34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","volume":"140","author":"AS Lok","year":"2011","unstructured":"Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840\u2013849","journal-title":"Gastroenterology"},{"key":"9799_CR35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","volume":"75","author":"F Donato","year":"1998","unstructured":"Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347\u2013354","journal-title":"Int J Cancer"},{"key":"9799_CR36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijc.25321","volume":"128","author":"LY Cho","year":"2011","unstructured":"Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer 2011;128:176\u2013184","journal-title":"Int J Cancer"},{"key":"9799_CR37","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/annonc\/mdu020","volume":"25","author":"F Turati","year":"2014","unstructured":"Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol 2014;25:1526\u20131535","journal-title":"Ann Oncol"},{"key":"9799_CR38","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1054\/bjoc.2001.2140","volume":"85","author":"V Bagnardi","year":"2001","unstructured":"Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001;85:1700\u20131705","journal-title":"Br J Cancer"},{"key":"9799_CR39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ypmed.2003.11.027","volume":"38","author":"G Corrao","year":"2004","unstructured":"Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004;38:613\u2013619","journal-title":"Prev Med"},{"key":"9799_CR40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","volume":"42","author":"JA Marrero","year":"2005","unstructured":"Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005;42:218\u2013224","journal-title":"J Hepatol"},{"key":"9799_CR41","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/ijc.26255","volume":"130","author":"T Shimazu","year":"2012","unstructured":"Shimazu T, Sasazuki S, Wakai K, Tamakoshi A, Tsuji I, Sugawara Y, et al. Alcohol drinking and primary liver cancer: a pooled analysis of four Japanese cohort studies. Int J Cancer 2012;130:2645\u20132653","journal-title":"Int J Cancer"},{"key":"9799_CR42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/1471-2407-11-446","volume":"11","author":"GA Heckley","year":"2011","unstructured":"Heckley GA, Jarl J, Asamoah BO. G-Gerdtham U. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer 2011;11:446","journal-title":"BMC Cancer"},{"key":"9799_CR43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ajg.2010.477","volume":"106","author":"K Berman","year":"2011","unstructured":"Berman K, Tandra S, Vuppalanchi R, Ghabril M, Sandrasegaran K, Nguyen J, et al. Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol 2011;106:899\u2013906","journal-title":"Am J Gastroenterol"},{"key":"9799_CR44","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1111\/j.1530-0277.2000.tb00015.x","volume":"24","author":"Y Shimauchi","year":"2000","unstructured":"Shimauchi Y, Tanaka M, Koga K, Itano S, Ishii K, Kumashiro R, et al. Clinical characteristics of patients in their 40\u00a0s with HCV antibody-positive hepatocellular carcinoma. Alcohol Clin Exp Res 2000;24:64S\u201367S","journal-title":"Alcohol Clin Exp Res"},{"key":"9799_CR45","unstructured":"Zhu GT, Lou GQ, Shi JP. To investigate the relationship of alcohol intake and hepatocellular carcinoma among patients with hepatitis B virus infection. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011;25:328\u2013330 (in Chinese)"},{"key":"9799_CR46","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.27508","volume":"131","author":"WL Shih","year":"2012","unstructured":"Shih WL, Chang HC, Liaw YF, Lin SM, Lee SD, Chen PJ, et al. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer 2012;131:2612\u20132621","journal-title":"Int J Cancer"},{"key":"9799_CR47","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cgh.2010.06.027","volume":"8","author":"R Loomba","year":"2010","unstructured":"Loomba R, Yang HI, Su J, Brenner D, Iloeje U, Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010;8:891\u2013898","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9799_CR48","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/ijerph7041366","volume":"7","author":"M Balbi","year":"2010","unstructured":"Balbi M, Donadon V, Ghersetti M, Grazioli S, Valentina GD, Gardenal R, et al. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health 2010;7:1366\u20131378","journal-title":"Int J Environ Res Public Health"},{"key":"9799_CR49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CEJ.0000000000000038","volume":"24","author":"J Chen","year":"2015","unstructured":"Chen J, Han Y, Xu C, Xiao T, Wang B. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev 2015;24:89\u201399","journal-title":"Eur J Cancer Prev"},{"key":"9799_CR50","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1111\/j.1572-0241.2001.04054.x","volume":"96","author":"HB El-Serag","year":"2001","unstructured":"El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001;96:2462\u20132467","journal-title":"Am J Gastroenterol"},{"key":"9799_CR51","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","volume":"130","author":"C Wang","year":"2012","unstructured":"Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012;130:1639\u20131648","journal-title":"Int J Cancer"},{"key":"9799_CR52","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2010.04271.x","volume":"31","author":"D Saunders","year":"2010","unstructured":"Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: the association between obesity and hepatocellular carcinoma\u2014epidemiological evidence. Aliment Pharmacol Ther 2010;31:1051\u20131063","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR53","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6603932","volume":"97","author":"SC Larsson","year":"2007","unstructured":"Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta- analysis of cohort studies. Br J Cancer 2007;97:1005\u20131008","journal-title":"Br J Cancer"},{"key":"9799_CR54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/MCG.0b013e3182a030c4","volume":"48","author":"R Jinjuvadia","year":"2014","unstructured":"Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol 2014;48:172\u2013177","journal-title":"J Clin Gastroenterol"},{"key":"9799_CR55","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","volume":"59","author":"RJ Wong","year":"2014","unstructured":"Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014;59:2188\u2013195","journal-title":"Hepatology"},{"key":"9799_CR56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gut.2008.164053","volume":"58","author":"T Ohki","year":"2009","unstructured":"Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009;58:839\u2013844","journal-title":"Gut"},{"key":"9799_CR57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.cgh.2014.08.013","volume":"13","author":"S Mittal","year":"2015","unstructured":"Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal trends of non-alcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594\u2013601","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 19","key":"9799_CR58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00535-008-2262-x","volume":"44","author":"E Hashimoto","year":"2009","unstructured":"Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009;44(Suppl 19):89\u201395","journal-title":"J Gastroenterol"},{"key":"9799_CR59","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cgh.2011.01.023","volume":"9","author":"K Yasui","year":"2011","unstructured":"Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428\u2013433","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9799_CR60","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/MEG.0b013e32835eb8d4","volume":"25","author":"W Ren","year":"2013","unstructured":"Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol 2013;25:830\u2013841","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9799_CR61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1440-1746.1996.tb00056.x","volume":"11","author":"SM Shrestha","year":"1996","unstructured":"Shrestha SM, Okuda K, Uchida T, Maharjan KG, Shrestha S, Joshi BL, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996;11:170\u2013179","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR62","first-page":"11","volume":"72","author":"IW Simson","year":"1987","unstructured":"Simson IW. The causes and consequences of chronic hepatic venous outflow obstruction. S Afr Med J 1987;72:11\u201314","journal-title":"S Afr Med J"},{"key":"9799_CR63","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020\u20131022","journal-title":"Hepatology"},{"key":"9799_CR64","first-page":"311","volume":"19","author":"P Ferenci","year":"2010","unstructured":"Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010;19:311\u2013317","journal-title":"J Gastrointestin Liver Dis"},{"key":"9799_CR65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jgh.12716","volume":"30","author":"S Meer van","year":"2015","unstructured":"van Meer S, de Man RA, van den Berg AP, Houwen RH, Linn FH, van Oijen MG, et al. No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up. J Gastroenterol Hepatol 2015;30:535\u2013539","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR66","first-page":"926","volume":"57","author":"YM Guo","year":"2010","unstructured":"Guo YM, Wei WY, Shen XZ. Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Hepatogastroenterology 2010;57:926\u2013931","journal-title":"Hepatogastroenterology"},{"key":"9799_CR67","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1177\/147323001003800304","volume":"38","author":"H Qin","year":"2010","unstructured":"Qin H, Liu B, Shi T, Liu Y, Sun Y, Ma Y. Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: a meta-analysis. J Int Med Res 2010;38:760\u2013768","journal-title":"J Int Med Res"},{"key":"9799_CR68","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/aje\/kwm315","volume":"167","author":"DL White","year":"2008","unstructured":"White DL, Li D, Nurgalieva Z, El-Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol 2008;167:377\u2013389","journal-title":"Am J Epidemiol"},{"key":"9799_CR69","unstructured":"Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl 1987;7:1\u2013440"},{"key":"9799_CR70","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1383-5742(00)00027-2","volume":"462","author":"CP Wild","year":"2000","unstructured":"Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000;462:381\u2013393","journal-title":"Mutat Res"},{"key":"9799_CR71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2009.08.024","volume":"286","author":"A Plymoth","year":"2009","unstructured":"Plymoth A, Viviani S, Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett 2009;286:15\u201321","journal-title":"Cancer Lett"},{"key":"9799_CR72","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.bjc.6600584","volume":"87","author":"CA Sun","year":"2002","unstructured":"Sun CA, Wu DM, Wang LY, Chen CJ, You SL, Santella RM. Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan. Br J Cancer 2002;87:966\u2013970","journal-title":"Br J Cancer"},{"key":"9799_CR73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ije\/11.2.112","volume":"11","author":"J Bulatao-Jayme","year":"1982","unstructured":"Bulatao-Jayme J, Almero EM, Castro MC, Jardeleza MT, Salamat LA. A case\u2013control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 1982;11:112\u2013119","journal-title":"Int J Epidemiol"},{"key":"9799_CR74","first-page":"3","volume":"3","author":"GS Qian","year":"1994","unstructured":"Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People\u2019s Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3\u201310","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9799_CR75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0140-6736(92)91528-G","volume":"339","author":"RK Ross","year":"1992","unstructured":"Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943\u2013946","journal-title":"Lancet"},{"key":"9799_CR76","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/1055-9965.EPI-04-0380","volume":"14","author":"SY Kuang","year":"2005","unstructured":"Kuang SY, Lekawanvijit S, Maneekarn N, Thongsawat S, Brodovicz K, Nelson K, et al. Hepatitis B 1762T\/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005;14:380\u2013384","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9799_CR77","unstructured":"U.S. Department of Health and Human Service. SURGEN GENERAL. GOV. The Health Consequences of smoking\u201350 years of progress: a report of the surgeon general, 2014. http:\/\/www.surgeongeneral.gov\/library\/reports\/50-years-of-progress\/ . Accessed 16 April 2017"},{"key":"9799_CR78","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ije\/dyp280","volume":"38","author":"YC Lee","year":"2009","unstructured":"Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 2009;38:1497\u20131511","journal-title":"Int J Epidemiol"},{"key":"9799_CR79","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cgh.2013.04.039","volume":"11","author":"F Bravi","year":"2013","unstructured":"Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013;11:1413\u20131421","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9799_CR80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/CEJ.0b013e3283447497","volume":"20","author":"M Fon Sing","year":"2011","unstructured":"Fon Sing M, Yang WS, Gao S, Gao J, Xiang YB. Epidemiological studies of the association between tea drinking and primary liver cancer: a meta-analysis. Eur J Cancer Prev 2011;20:157\u2013165","journal-title":"Eur J Cancer Prev"},{"key":"9799_CR81","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0278-6915(02)00029-7","volume":"40","author":"C Cavin","year":"2002","unstructured":"Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 2002;40:1155\u20131163","journal-title":"Food Chem Toxicol"},{"key":"9799_CR82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.fitote.2009.10.003","volume":"81","author":"P Muriel","year":"2010","unstructured":"Muriel P, Arauz J. Coffee and liver diseases. Fitoterapia 2010;81:297\u2013305","journal-title":"Fitoterapia"},{"key":"9799_CR83","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jnutbio.2010.03.011","volume":"22","author":"U Boettler","year":"2011","unstructured":"Boettler U, Sommerfeld K, Volz N, Pahlke G, Teller N, Somoza V, et al. Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-dependent gene expression. J Nutr Biochem 2011;22:426\u2013440","journal-title":"J Nutr Biochem"},{"key":"9799_CR84","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1039\/C4FO00042K","volume":"5","author":"IA Ludwig","year":"2014","unstructured":"Ludwig IA, Clifford MN, Lean ME, Ashihara H, Crozier A. Coffee: biochemistry and potential impact on health. Food Funct 2014;5:1695\u20131717","journal-title":"Food Funct"},{"key":"9799_CR85","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrc2641","volume":"9","author":"CS Yang","year":"2009","unstructured":"Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009;9:429\u2013439","journal-title":"Nat Rev Cancer"},{"key":"9799_CR86","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00268-008-9526-8","volume":"32","author":"SW Moore","year":"2008","unstructured":"Moore SW, Davidson A, Hadley GP, Kruger M, Poole J, Stones D, et al. Malignant liver tumors in South African children: a national audit. World J Surg 2008;32:1389\u20131395","journal-title":"World J Surg"},{"key":"9799_CR87","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-3016.1990.tb00651.x","volume":"4","author":"JR Mann","year":"1990","unstructured":"Mann JR, Kasthuri N, Raafat F, Pincott JR, Parkes SE, Muir KR, et al. Malignant hepatic tumours in children: incidence, clinical features and aetiology. Paediatr Perinat Epidemiol 1990;4:276\u2013289","journal-title":"Paediatr Perinat Epidemiol"},{"key":"9799_CR88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(85)91976-2","volume":"1","author":"AJ Hall","year":"1985","unstructured":"Hall AJ, Winter PD, Wright R. Mortality of hepatitis B positive blood donors in England and Wales. Lancet 1985;1:91\u201393","journal-title":"Lancet"},{"key":"9799_CR89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-642-10858-7_6","volume":"188","author":"MH Chang","year":"2011","unstructured":"Chang MH. Hepatitis B virus and cancer prevention. Recent Results Cancer Res 2011;188:75\u201384","journal-title":"Recent Results Cancer Res"},{"key":"9799_CR90","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1111\/petr.12223","volume":"18","author":"S Malik","year":"2014","unstructured":"Malik S, Dekio F, Wen JW. Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir. Pediatr Transplant 2014;18:E64\u2013E68","journal-title":"Pediatr Transplant."},{"key":"9799_CR91","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.transproceed.2011.01.129","volume":"43","author":"TM Manzia","year":"2011","unstructured":"Manzia TM, Angelico R, Toti L, Cillis A, Ciano P, Orlando G, et al. Glycogen storage disease type Ia and VI associated with hepatocellular carcinoma: two case reports. Transplant Proc 2011;43:1181\u20131183","journal-title":"Transplant Proc"},{"key":"9799_CR92","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/his.12312","volume":"64","author":"Y Zen","year":"2014","unstructured":"Zen Y, Vara R, Portmann B, Hadzic N. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Histopathology 2014;64:671\u2013682","journal-title":"Histopathology"},{"key":"9799_CR93","unstructured":"Kudo M, Namki I, Ichida T, Ku Y, Kokudo N, Sakamoto M, et al. 19th Zenkoku genpatsusei kangan tsuiseki chosa hokoku (2006\u20132007). Kanzo 2016; 57:45\u201373 (Japanese)"},{"key":"9799_CR94","unstructured":"POLARIS Observatory. Hepatitis C. http:\/\/polarisobservatory.org\/polaris\/hepC.htm . Accessed 16 April 2017"},{"key":"9799_CR95","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000342749","volume":"1","author":"M Kudo","year":"2012","unstructured":"Kudo M. Japan\u2019s successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. Liver Cancer 2012;1:141\u2013143","journal-title":"Liver Cancer"},{"key":"9799_CR96","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jceh.2014.05.013","volume":"4","author":"SK Acharya","year":"2014","unstructured":"Acharya SK. Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol 2014;4:S27\u2013S33","journal-title":"J Clin Exp Hepatol"},{"key":"9799_CR97","unstructured":"International Agency for Research on Cancer. Cancer incidence in five continents. http:\/\/Ci5.iarc.fr\/ . Accessed 16 April 2017"},{"key":"9799_CR98","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000231886","volume":"77","author":"SB Paul","year":"2009","unstructured":"Paul SB, Chalamalasetty SB, Vishnubhatla S, Madan K, Gamanagatti SR, Batra Y, et al. Clinical profile, etiology and therapeutic outcome in 324 hepatocellular cancer in India. Oncology 2009;77:162\u2013171","journal-title":"Oncology"},{"key":"9799_CR99","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1046\/j.1440-1746.2001.02476.x","volume":"16","author":"SK Sarin","year":"2001","unstructured":"Sarin SK, Thakur V, Guptan RC, Saigal S, Malhotra V, Thyagarajan SP, et al. Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. J Gastroenterol Hepatol 2001;16:666\u2013673","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1440-1746.2007.04908.x","volume":"22","author":"M Kumar","year":"2007","unstructured":"Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol 2007;22:1104\u20131111","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR101","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5694\/j.1326-5377.2000.tb139267.x","volume":"173","author":"MG Law","year":"2000","unstructured":"Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978\u20131997: increasing incidence and mortality. Med J Aust 2000;173:403\u2013405","journal-title":"Med J Aust"},{"key":"9799_CR102","unstructured":"Tracey E, Chen S, Baker D, Bishop J, Jelfs P. Cancer in New South Wales: Incidence and Mortality 2004. Cancer Institute, NSW, 2006"},{"key":"9799_CR103","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1111\/j.1440-1746.2011.06785.x","volume":"26","author":"SR Walter","year":"2011","unstructured":"Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011;26:1757\u20131764","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR104","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1753-6405.2007.00121.x","volume":"31","author":"J Amin","year":"2007","unstructured":"Amin J, O\u2019Connell D, Bartlett M, Tracey E, Kaldor J, Law M, et al. Liver cancer and hepatitis B and C in New South Wales, 1990\u20132002: a linkage study. Aust N Z J Public Health 2007;31:475\u2013482","journal-title":"Aust N Z J Public Health"},{"key":"9799_CR105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2188\/jea.JE20100190","volume":"21","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011;21:401\u2013416","journal-title":"J Epidemiol"},{"key":"9799_CR106","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.7314\/APJCP.2013.14.12.7251","volume":"14","author":"JH Fan","year":"2013","unstructured":"Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, et al. Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev 2013;14:7251\u20137256","journal-title":"Asian Pac J Cancer Prev"},{"key":"9799_CR107","unstructured":"Zhou X, Tang Z, Yu Y. Changing prognosis of primary liver cancer: some aspects to improve long-term survival. Zhonghua Zhong Liu Za Zhi 1996;18:211\u2013213 (Article in Chinese)"},{"key":"9799_CR108","first-page":"346","volume":"12","author":"J Lin","year":"1991","unstructured":"Lin J. A study on aetiological factors of primary hepato-carcinoma in Tianjin China. Zhonghua Liu Xing Bing Xue Za Zhi 1991;12:346\u2013349","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi."},{"key":"9799_CR109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.510310211","volume":"31","author":"MF Yuen","year":"2000","unstructured":"Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330\u2013335","journal-title":"Hepatology"},{"key":"9799_CR110","unstructured":"Park JW. Hepatocellular carcinoma in Korea: introduction and overview. Korean J Gastroenterol 2005;45:217\u2013226 (Article in Korean)"},{"key":"9799_CR111","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s10552-012-9986-x","volume":"23","author":"I Meredith","year":"2012","unstructured":"Meredith I, Sarfati D, Ikeda T, Blakely T. Cancer in Pacific people in New Zealand. Cancer Causes Control 2012;23:1173\u20131184","journal-title":"Cancer Causes Control"},{"key":"9799_CR112","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/ijc.22045","volume":"119","author":"SN Lu","year":"2006","unstructured":"Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946\u20131952","journal-title":"Int J Cancer"},{"key":"9799_CR113","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","volume":"336","author":"MH Chang","year":"1997","unstructured":"Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855\u20131859","journal-title":"N Engl J Med"},{"key":"9799_CR114","first-page":"e6894","volume":"12","author":"A Zidan","year":"2012","unstructured":"Zidan A, Scheuerlein H, Sch\u00fcle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in Iran and worldwide. Hepat Mon 2012;12:e6894","journal-title":"Hepat Mon"},{"key":"9799_CR115","doi-asserted-by":"crossref","first-page":"5942306","DOI":"10.1155\/2016\/5942306","volume":"2016","author":"AB Hafeez Bhatti","year":"2016","unstructured":"Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: national Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306","journal-title":"Gastroenterol Res Pract"},{"key":"9799_CR116","unstructured":"WHO. Cancer country profiles 2014. http:\/\/www.who.int\/cancer\/country-profiles\/en\/ . Accessed 16 April 2017"},{"key":"9799_CR117","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/sj.bjc.6603649","volume":"96","author":"SA Raza","year":"2007","unstructured":"Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007;96:1127\u20131134","journal-title":"Br J Cancer"},{"key":"9799_CR118","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1478-3231.2007.01646.x","volume":"28","author":"VT Nguyen","year":"2008","unstructured":"Nguyen VT, Law MG, Dore GJ. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int 2008;28:525\u2013531","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"9799_CR119","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000333278","volume":"81","author":"O Baatarkhuu","year":"2011","unstructured":"Baatarkhuu O, Kim DY, Bat-Ireedui P, Han KH. Current situation of hepatocellular carcinoma in Mongolia. Oncology 2011;81(Suppl 1):148\u2013151","journal-title":"Oncology"},{"key":"9799_CR120","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","volume":"62","author":"C Martel de","year":"2015","unstructured":"de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015;62:1190\u20131200","journal-title":"Hepatology"},{"key":"9799_CR121","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1440-1746.2009.06167.x","volume":"25","author":"Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma","year":"2010","unstructured":"Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010;25:657\u2013663","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR122","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1665-2681(19)30922-6","volume":"11","author":"VWS Wong","year":"2012","unstructured":"Wong VWS, Chan HLY. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Ann Hepatol 2012;11:284\u2013293","journal-title":"Ann Hepatol"},{"key":"9799_CR123","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.05.021","volume":"57","author":"YH Ni","year":"2012","unstructured":"Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012;57:730\u2013735","journal-title":"J Hepatol"},{"key":"9799_CR124","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","volume":"310","author":"CJ Chiang","year":"2013","unstructured":"Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013;310:974\u2013976","journal-title":"JAMA"},{"key":"9799_CR125","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","volume":"27","author":"X Liang","year":"2009","unstructured":"Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550\u20136557","journal-title":"Vaccine"},{"key":"9799_CR126","doi-asserted-by":"crossref","first-page":"e1001774","DOI":"10.1371\/journal.pmed.1001774","volume":"11","author":"C Qu","year":"2014","unstructured":"Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med 2014;11:e1001774","journal-title":"PLoS Med"},{"key":"9799_CR127","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65\u201373","journal-title":"JAMA"},{"key":"9799_CR128","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"JD Chen","year":"2010","unstructured":"Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138:1747\u20131754","journal-title":"Gastroenterology"},{"key":"9799_CR129","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521\u20131531","journal-title":"N Engl J Med"},{"key":"9799_CR130","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","volume":"53","author":"GV Papatheodoridis","year":"2010","unstructured":"Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348\u2013356","journal-title":"J Hepatol"},{"key":"9799_CR131","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","volume":"38","author":"AK Singal","year":"2013","unstructured":"Singal AK, Salameh H, Kuo YF. Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013;38:98\u2013106","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR132","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2010.02.026","volume":"53","author":"JR Eun","year":"2010","unstructured":"Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53:118\u2013125","journal-title":"J Hepatol"},{"key":"9799_CR133","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98\u2013107","journal-title":"Hepatology"},{"key":"9799_CR134","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.27630","volume":"61","author":"CJ Chiang","year":"2015","unstructured":"Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, et al. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology 2015;61:1154\u20131162","journal-title":"Hepatology"},{"key":"9799_CR135","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","volume":"63","author":"JY Cho","year":"2014","unstructured":"Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut 2014;63:1943\u20131950","journal-title":"Gut"},{"key":"9799_CR136","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jhep.2012.06.025","volume":"57","author":"A Aghemo","year":"2012","unstructured":"Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol 2012;57:1326\u20131335","journal-title":"J Hepatol"},{"key":"9799_CR137","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12072-016-9714-9","volume":"10","author":"Y Kong","year":"2016","unstructured":"Kong Y, You H, Jia J. Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense. Hepatol Int 2016;10:239\u2013241","journal-title":"Hepatol Int"},{"key":"9799_CR138","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2014.11.031","volume":"62","author":"GA Kim","year":"2015","unstructured":"Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J, et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 2015;62:1092\u20131099","journal-title":"J Hepatol"},{"key":"9799_CR139","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","volume":"52","author":"TR Morgan","year":"2010","unstructured":"Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833\u2013844","journal-title":"Hepatology"},{"key":"9799_CR140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","volume":"34","author":"C Camm\u00e0","year":"2001","unstructured":"Camm\u00e0 C, Giunta M, Andreone P, Crax\u00ec A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593\u2013602","journal-title":"J Hepatol"},{"key":"9799_CR141","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1478-3231.2006.01260.x","volume":"26","author":"M Akamatsu","year":"2006","unstructured":"Akamatsu M, Yoshida H, Shiina S, Teratani T, Obi S, Tateishi R, et al. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 2006;26:536\u2013542","journal-title":"Liver Int"},{"key":"9799_CR142","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/135965350601100811","volume":"11","author":"ML Yu","year":"2006","unstructured":"Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, et al. A sustained virological response to interferon or interferon\/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985\u2013994","journal-title":"Antivir Ther"},{"key":"9799_CR143","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124\u20131130","journal-title":"Hepatology"},{"key":"9799_CR144","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.510270529","volume":"27","author":"A Kasahara","year":"1998","unstructured":"Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394\u20131402","journal-title":"Hepatology"},{"key":"9799_CR145","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/cncr.20537","volume":"101","author":"A Makiyama","year":"2004","unstructured":"Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:1616\u20131622","journal-title":"Cancer"},{"key":"9799_CR146","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","volume":"142","author":"Y Shiratori","year":"2005","unstructured":"Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105\u2013114","journal-title":"Ann Intern Med"},{"key":"9799_CR147","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.2003.030353","volume":"53","author":"H Yoshida","year":"2004","unstructured":"Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004;53:425\u2013430","journal-title":"Gut"},{"key":"9799_CR148","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","volume":"64","author":"HB El-Serag","year":"2016","unstructured":"El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016;64:130\u2013137","journal-title":"Hepatology"},{"key":"9799_CR149","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/jac\/dks269","volume":"67","author":"KC Chang","year":"2012","unstructured":"Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother 2012;67:2766\u20132772","journal-title":"J Antimicrob Chemother"},{"key":"9799_CR150","unstructured":"van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fern\u00e1ndez-Rodr\u00edguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2016; (Epub ahead of print)"},{"key":"9799_CR151","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/hep.26087","volume":"57","author":"Y Arase","year":"2013","unstructured":"Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on the risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013;57:964\u2013973","journal-title":"Hepatology"},{"key":"9799_CR152","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517\u2013524","journal-title":"Ann Intern Med"},{"key":"9799_CR153","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303\u20131313","journal-title":"Gastroenterology"},{"key":"9799_CR154","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1023\/A:1024196201684","volume":"48","author":"A Arif","year":"2003","unstructured":"Arif A, Levine RA, Sanderson SO, Bank L, Velu RP, Shah A, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003;48:1425\u20131430","journal-title":"Dig Dis Sci"},{"key":"9799_CR155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.humpath.2003.08.012","volume":"35","author":"S Pol","year":"2004","unstructured":"Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004;35:107\u2013112","journal-title":"Hum Pathol"},{"key":"9799_CR156","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2036.2008.03620.x","volume":"27","author":"GT Everson","year":"2008","unstructured":"Everson GT, Balart L, Lee SS, Reindollar RW, Shiffman ML, Minuk GY, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008;27:542\u2013551","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR157","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","volume":"49","author":"SL George","year":"2009","unstructured":"George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009;49:729\u2013738","journal-title":"Hepatology"},{"key":"9799_CR158","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","volume":"15","author":"M Bourli\u00e8re","year":"2015","unstructured":"Bourli\u00e8re M, Bronowicki JP, de Ledinghen V, H\u00e9zode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397\u2013404","journal-title":"Lancet Infect Dis"},{"key":"9799_CR159","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015;149:649\u2013659","journal-title":"Gastroenterology"},{"key":"9799_CR160","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3\u00a0+). Hepatology 2016;63:1430\u20131441","journal-title":"Hepatology"},{"key":"9799_CR161","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000282080","volume":"28","author":"SSF Bellentani","year":"2010","unstructured":"Bellentani SSF, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155\u2013161","journal-title":"Dig Dis"},{"key":"9799_CR162","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148\u20131155","journal-title":"J Hepatol"},{"key":"9799_CR163","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","volume":"116","author":"CAYZ Matteoni","year":"1999","unstructured":"Matteoni CAYZ, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413\u20131419","journal-title":"Gastroenterology"},{"key":"9799_CR164","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.5858\/132.11.1761","volume":"132","author":"GBE Guzman","year":"2008","unstructured":"Guzman GBE, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761\u20131766","journal-title":"Arch Pathol Lab Med"},{"key":"9799_CR165","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1746.2008.05640.x","volume":"24","author":"S Yatsuji","year":"2009","unstructured":"Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248\u2013254","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR166","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","volume":"51","author":"MS Ascha","year":"2010","unstructured":"Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972\u20131978","journal-title":"Hepatology"},{"key":"9799_CR167","first-page":"9217","volume":"20","author":"A Scalera","year":"2014","unstructured":"Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol 2014;20:9217\u20139228","journal-title":"World J Gastroenterol"},{"key":"9799_CR168","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","volume":"35","author":"K Esposito","year":"2012","unstructured":"Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012;35:2402\u20132411","journal-title":"Diabetes Care"},{"key":"9799_CR169","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jjco\/hyr198","volume":"42","author":"K Tanaka","year":"2012","unstructured":"Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Ito H, Wakai K, et al. Obesity and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2012;42:212\u2013221","journal-title":"Jpn J Clin Oncol"},{"key":"9799_CR170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/dmrr.1291","volume":"28","author":"P Wang","year":"2012","unstructured":"Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012;28:109\u2013122","journal-title":"Diabetes Metab Res Rev"},{"key":"9799_CR171","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.ejca.2012.02.063","volume":"48","author":"Y Chen","year":"2012","unstructured":"Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer 2012;48:2137\u20132145","journal-title":"Eur J Cancer"},{"key":"9799_CR172","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0016-5085(94)90235-6","volume":"107","author":"BR Bacon","year":"1994","unstructured":"Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103\u20131109","journal-title":"Gastroenterology"},{"key":"9799_CR173","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1159\/000375353","volume":"33","author":"S Traussnigg","year":"2015","unstructured":"Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, et al. Challenges and Management of Liver Cirrhosis: practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Dig Dis 2015;33:598\u2013607","journal-title":"Dig Dis"},{"key":"9799_CR174","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/cncr.29912","volume":"122","author":"DK DePeralta","year":"2016","unstructured":"DePeralta DK, Wei L, Ghoshal S, Schmidt B, Lauwers GY, Lanuti M, et al. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 2016;122:1216\u20131227","journal-title":"Cancer"},{"key":"9799_CR175","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005\u20132023","journal-title":"Hepatology"},{"key":"9799_CR176","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263\u20132273","journal-title":"JAMA"},{"key":"9799_CR177","first-page":"1388","volume":"64","author":"European Association for the Study of the Liver; (EASL)1; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver; (EASL)1; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388\u20131402","journal-title":"J Hepatol"},{"key":"9799_CR178","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2009.07.009","volume":"51","author":"JC Wu","year":"2009","unstructured":"Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890\u2013897","journal-title":"J Hepatol"},{"key":"9799_CR179","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1572-0241.2008.01872.x","volume":"103","author":"IF Hung","year":"2008","unstructured":"Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008;103:1663\u20131673","journal-title":"Am J Gastroenterol"},{"key":"9799_CR180","doi-asserted-by":"crossref","first-page":"e0148493","DOI":"10.1371\/journal.pone.0148493","volume":"11","author":"IF Hung","year":"2016","unstructured":"Hung IF, Wong DK, Poon RT, Fong DY, Chui AH, Seto WK, et al. Risk factors and post-resection independent predictive score for the recurrence of hepatitis B-related hepatocellular carcinoma. PLoS One 2016;11:e0148493","journal-title":"PLoS One"},{"key":"9799_CR181","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.sla.0000245829.00977.45","volume":"245","author":"CM Lo","year":"2007","unstructured":"Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831\u2013842","journal-title":"Ann Surg"},{"key":"9799_CR182","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e3182363ff9","volume":"255","author":"LT Chen","year":"2012","unstructured":"Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012;255:8\u201317","journal-title":"Ann Surg"},{"key":"9799_CR183","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cncr.20004","volume":"100","author":"SM Lin","year":"2004","unstructured":"Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376\u2013382","journal-title":"Cancer"},{"key":"9799_CR184","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/hepr.12169","volume":"44","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, et al. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res 2014;44:608\u2013620","journal-title":"Hepatol Res."},{"key":"9799_CR185","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","volume":"31","author":"J Yin","year":"2013","unstructured":"Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013;31:3647\u20133655","journal-title":"J Clin Oncol"},{"key":"9799_CR186","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1440-1746.2006.04707.x","volume":"22","author":"T Kuzuya","year":"2007","unstructured":"Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1929\u20131935","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR187","first-page":"217","volume":"59","author":"CY Piao","year":"2005","unstructured":"Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma\u2013using an untreated, matched control cohort. Acta Med Okayama 2005;59:217\u2013224","journal-title":"Acta Med Okayama"},{"key":"9799_CR188","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","volume":"308","author":"CY Wu","year":"2012","unstructured":"Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906\u20131914","journal-title":"JAMA"},{"key":"9799_CR189","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1245\/s10434-012-2803-7","volume":"20","author":"G Huang","year":"2013","unstructured":"Huang G, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol 2013;20:1482\u20131490","journal-title":"Ann Surg Oncol"},{"key":"9799_CR190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","volume":"43","author":"JW Jang","year":"2006","unstructured":"Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233\u2013240","journal-title":"Hepatology"},{"key":"9799_CR191","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.510250116","volume":"25","author":"T Kumada","year":"1997","unstructured":"Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87\u201392","journal-title":"Hepatology"},{"key":"9799_CR192","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O","volume":"89","author":"RT Poon","year":"2000","unstructured":"Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500\u2013507","journal-title":"Cancer"},{"key":"9799_CR193","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/archsurg.135.12.1456","volume":"135","author":"M Sakon","year":"2000","unstructured":"Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 2000;135:1456\u20131459","journal-title":"Arch Surg"},{"key":"9799_CR194","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/jhep.2000.9409","volume":"32","author":"K Ikeda","year":"2000","unstructured":"Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228\u2013232","journal-title":"Hepatology"},{"key":"9799_CR195","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-134-10-200105150-00010","volume":"134","author":"S Kubo","year":"2001","unstructured":"Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963\u2013967","journal-title":"Ann Intern Med"},{"key":"9799_CR196","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-138-4-200302180-00008","volume":"138","author":"Y Shiratori","year":"2003","unstructured":"Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299\u2013306","journal-title":"Ann Intern Med"},{"key":"9799_CR197","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1440-1746.2005.03925.x","volume":"20","author":"CH Hung","year":"2005","unstructured":"Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:1553\u20131559","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR198","first-page":"529","volume":"59","author":"T Ishikawa","year":"2012","unstructured":"Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, et al. Combination PEG-IFN a-2b\/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 2012;59:529\u2013532","journal-title":"Hepatogastroenterology"},{"key":"9799_CR199","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","volume":"44","author":"V Mazzaferro","year":"2006","unstructured":"Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543\u20131554","journal-title":"Hepatology"},{"key":"9799_CR200","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000082097","volume":"48","author":"Y Sakaguchi","year":"2005","unstructured":"Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:64\u201370","journal-title":"Intervirology"},{"key":"9799_CR201","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000082098","volume":"48","author":"S Nishiguchi","year":"2005","unstructured":"Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Ntervirology 2005;48:71\u201375","journal-title":"Ntervirology"},{"key":"9799_CR202","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jgh.12925","volume":"30","author":"N Kanogawa","year":"2015","unstructured":"Kanogawa N, Ogasawara S, Chiba T, Saito T, Motoyama T, Suzuki E, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol 2015;30:1197\u20131204","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR203","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016;65:719\u2013726","journal-title":"J Hepatol"},{"key":"9799_CR204","doi-asserted-by":"crossref","unstructured":"The ANRS Collaborative Study Group on Hepatocellular Carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016;65:734\u2013740","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"9799_CR205","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727\u2013733","journal-title":"J Hepatol"},{"key":"9799_CR206","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2016.07.043","volume":"65","author":"T Minami","year":"2016","unstructured":"Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 2016;65:1272\u20131273","journal-title":"J Hepatol"},{"key":"9799_CR207","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/hep.21341","volume":"44","author":"K Hasegawa","year":"2006","unstructured":"Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006;44:891\u2013895","journal-title":"Hepatology"},{"key":"9799_CR208","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344\u20131354","journal-title":"Lancet Oncol"},{"key":"9799_CR209","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199606133342402","volume":"334","author":"Y Muto","year":"1996","unstructured":"Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561\u20131567","journal-title":"N Engl J Med"},{"key":"9799_CR210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000082093","volume":"48","author":"K Takai","year":"2005","unstructured":"Takai K, Okuno M, Yasuda I, Matsushima-Nishiwaki R, Uematsu T, Tsurumi H, et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 2005;48:39\u201345","journal-title":"Intervirology"},{"key":"9799_CR211","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00535-014-0956-9","volume":"50","author":"K Okita","year":"2015","unstructured":"Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 2015;50:191\u2013202","journal-title":"J Gastroenterol"},{"key":"9799_CR212","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00535-014-0996-1","volume":"50","author":"K Okita","year":"2015","unstructured":"Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, et al. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol 2015;50:667\u2013674","journal-title":"J Gastroenterol"},{"key":"9799_CR213","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12072-016-9704-y","volume":"10","author":"Y Takami","year":"2016","unstructured":"Takami Y, Eguchi S, Tateishi M, Ryu T, Mikagi K, Wada Y, et al. A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment. Hepatol Int 2016;10:799\u2013806","journal-title":"Hepatol Int"},{"key":"9799_CR214","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.292.3.358","volume":"292","author":"D Habu","year":"2004","unstructured":"Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004;292:358\u2013361","journal-title":"JAMA"},{"key":"9799_CR215","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cncr.21667","volume":"106","author":"T Mizuta","year":"2006","unstructured":"Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006;106:867\u2013872","journal-title":"Cancer"},{"key":"9799_CR216","first-page":"2073","volume":"54","author":"N Hotta","year":"2007","unstructured":"Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007;54:2073\u20132077","journal-title":"Hepatogastroenterology"},{"key":"9799_CR217","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.24430","volume":"54","author":"H Yoshida","year":"2011","unstructured":"Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011;54:532\u2013540","journal-title":"Hepatology"},{"key":"9799_CR218","doi-asserted-by":"crossref","unstructured":"Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635\u2013654","DOI":"10.1148\/radiol.14132361"},{"key":"9799_CR219","doi-asserted-by":"crossref","unstructured":"Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624","DOI":"10.1371\/journal.pmed.1001624"},{"key":"9799_CR220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1155\/2015\/563893","volume":"29","author":"K Khalili","year":"2015","unstructured":"Khalili K, Menezes R, Kim TK, Kochak Yazdi L, Jang HJ, Sharma S, et al. The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a canadian centre and determinants of its success. Can J Gastroenterol Hepatol 2015;29:267\u2013273","journal-title":"Can J Gastroenterol Hepatol"},{"key":"9799_CR221","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.48.2.251","volume":"48","author":"L Bolondi","year":"2001","unstructured":"Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251\u2013259","journal-title":"Gut"},{"key":"9799_CR222","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/apt.12370","volume":"38","author":"C Pocha","year":"2013","unstructured":"Pocha C, Dieperink E, McMaken K, Knott A, Thuras P, Ho S. Surveillance for hepatocellular cancer with ultrasonography vs. Computed tomography\u2013a randomised study. Aliment Pharmacol Ther 2013;38:303\u2013312","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR223","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2009.04014.x","volume":"30","author":"A Singal","year":"2009","unstructured":"Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37\u201347","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR224","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3348\/kjr.2016.17.1.7","volume":"17","author":"JH Yoon","year":"2016","unstructured":"Yoon JH, Park JW, Lee JM. Noninvasive diagnosis of hepatocellular carcinoma: Elaboration on korean liver cancer study group-national cancer center korea practice guidelines compared with other guidelines and remaining issues. Korean J Radiol 2016;17:7\u201324","journal-title":"Korean J Radiol"},{"key":"9799_CR225","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1572-0241.2006.00467.x","volume":"101","author":"A Colli","year":"2006","unstructured":"Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral ct, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513\u2013523","journal-title":"Am J Gastroenterol"},{"key":"9799_CR226","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00261-015-0592-8","volume":"41","author":"RF Hanna","year":"2016","unstructured":"Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, Sandhu RS, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY). 2016;41:71\u201390","journal-title":"Abdom Radiol (NY)"},{"key":"9799_CR227","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1053\/j.seminoncol.2012.05.010","volume":"39","author":"JM Lee","year":"2012","unstructured":"Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012;39:399\u2013409","journal-title":"Semin Oncol"},{"key":"9799_CR228","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2174\/1566524033479546","volume":"3","author":"WB Coleman","year":"2003","unstructured":"Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3:573\u2013588","journal-title":"Curr Mol Med"},{"key":"9799_CR229","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1148\/radiology.206.1.9423667","volume":"206","author":"K Ueda","year":"1998","unstructured":"Ueda K, Matsui O, Kawamori Y, Nakanuma Y, Kadoya M, Yoshikawa J, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998;206:161\u2013166","journal-title":"Radiology"},{"key":"9799_CR230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00261-011-9692-2","volume":"36","author":"JM Lee","year":"2011","unstructured":"Lee JM, Choi BI. Hepatocellular nodules in liver cirrhosis: mR evaluation. Abdom Imaging 2011;36:282\u2013289","journal-title":"Abdom Imaging"},{"key":"9799_CR231","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2214\/ajr.154.3.2154912","volume":"154","author":"S Tanaka","year":"1990","unstructured":"Tanaka S, Kitamura T, Fujita M, Nakanishi K, Okuda S. Color doppler flow imaging of liver tumors. AJR Am J Roentgenol 1990;154:509\u2013514","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR232","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1148\/radiology.182.1.1309217","volume":"182","author":"S Tanaka","year":"1992","unstructured":"Tanaka S, Kitamra T, Fujita M, Kasugai H, Inoue A, Ishiguro S. Small hepatocellular carcinoma: differentiation from adenomatous hyperplastic nodule with color doppler flow imaging. Radiology 1992;182:161\u2013165","journal-title":"Radiology"},{"key":"9799_CR233","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2214\/ajr.170.1.9423624","volume":"170","author":"K Koito","year":"1998","unstructured":"Koito K, Namieno T, Morita K. Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power doppler sonography. AJR Am J Roentgenol 1998;170:157\u2013161","journal-title":"AJR Am J Roentgenol"},{"issue":"Suppl 1","key":"9799_CR234","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000122600","volume":"51","author":"K Hatanaka","year":"2008","unstructured":"Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, sonazoid. Intervirology 2008;51(Suppl 1):61\u201369","journal-title":"Intervirology"},{"key":"9799_CR235","doi-asserted-by":"crossref","first-page":"W56","DOI":"10.2214\/AJR.14.14203","volume":"205","author":"M D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol 2015;205:W56\u2013W66","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR236","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.3748\/wjg.v20.i13.3590","volume":"20","author":"TK Kim","year":"2014","unstructured":"Kim TK, Jang HJ. Contrast-enhanced ultrasound in the diagnosis of nodules in liver cirrhosis. World J Gastroenterol 2014;20:3590\u20133596","journal-title":"World J Gastroenterol"},{"key":"9799_CR237","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000367775","volume":"5","author":"M Kudo","year":"2016","unstructured":"Kudo M. Defect reperfusion imaging with sonazoid\u00ae: a breakthrough in hepatocellular carcinoma. Liver Cancer 2016;5:1\u20137","journal-title":"Liver Cancer"},{"key":"9799_CR238","doi-asserted-by":"crossref","first-page":"W7","DOI":"10.2214\/AJR.06.1060","volume":"189","author":"SR Wilson","year":"2007","unstructured":"Wilson SR, Kim TK, Jang HJ, Burns PN. Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI. AJR Am J Roentgenol 2007;189:W7\u2013W12","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR239","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.ejrad.2015.05.020","volume":"84","author":"HJ Jang","year":"2015","unstructured":"Jang HJ, Kim TK, Burns PN, Wilson SR. CEUS: an essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma. Eur J Radiol 2015;84:1623\u20131635","journal-title":"Eur J Radiol"},{"key":"9799_CR240","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1148\/radiol.2443061520","volume":"224","author":"HJ Jang","year":"2007","unstructured":"Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007;224:898\u2013906","journal-title":"Radiology"},{"key":"9799_CR241","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1148\/radiol.10091210","volume":"257","author":"SR Wilson","year":"2010","unstructured":"Wilson SR, Burns PN. Microbubble-enhanced us in body imaging: what role? Radiology 2010;257:24\u201339","journal-title":"Radiology"},{"key":"9799_CR242","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/hep.23600","volume":"51","author":"R Vilana","year":"2010","unstructured":"Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, de Lope CR, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020\u20132029","journal-title":"Hepatology"},{"key":"9799_CR243","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/liv.12124","volume":"33","author":"M Galassi","year":"2013","unstructured":"Galassi M, Iavarone M, Rossi S, Bota S, Vavassori S, Rosa L, et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int 2013;33:771\u2013779","journal-title":"Liver Int"},{"key":"9799_CR244","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/2050640614538964","volume":"2","author":"I Sio de","year":"2014","unstructured":"de Sio I, Iadevaia MD, Vitale LM, Niosi M, Del Prete A, de Sio C, et al. Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: a single-center retrospective study. Unit Eur Gastroenterol J 2014;2:279\u2013287","journal-title":"Unit Eur Gastroenterol J"},{"key":"9799_CR245","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0035-1558787","volume":"36","author":"D Wildner","year":"2015","unstructured":"Wildner D, Bernatik T, Greis C, Seitz K, Neurath MF, Strobel D. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015;36:132\u2013139","journal-title":"Ultraschall Med"},{"key":"9799_CR246","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1007\/s13277-013-0948-z","volume":"34","author":"Y Niu","year":"2013","unstructured":"Niu Y, Huang T, Lian F, Li F. Contrast-enhanced ultrasonography for the diagnosis of small hepatocellular carcinoma: a meta-analysis and meta-regression analysis. Tumour Biol 2013;34:3667\u20133674","journal-title":"Tumour Biol"},{"key":"9799_CR247","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17090","volume":"17","author":"M Westwood","year":"2013","unstructured":"Westwood M, Joore M, Grutters J, Redekop K, Armstrong N, Lee K, et al. Contrast-enhanced ultrasound using SonoVue\u00ae (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013;17:1\u2013243","journal-title":"Health Technol Assess"},{"issue":"Suppl 1","key":"9799_CR248","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000173423","volume":"75","author":"K Hatanaka","year":"2008","unstructured":"Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008;75(Suppl 1):42\u201347","journal-title":"Oncology"},{"key":"9799_CR249","first-page":"515","volume":"17","author":"V Cantisani","year":"2015","unstructured":"Cantisani V, David E, Meloni FM, Dietrich CF, Badea R, Messineo D, et al. Recall strategies for patients found to have a nodule in cirrhosis: is there still a role for CEUS? Med Ultrason 2015;17:515\u2013520","journal-title":"Med Ultrason"},{"key":"9799_CR250","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00330-015-3900-3","volume":"26","author":"E Neri","year":"2016","unstructured":"Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 2016;26:921\u2013931","journal-title":"Eur Radiol"},{"issue":"Suppl 2","key":"9799_CR251","first-page":"S34","volume":"17","author":"JM Lee","year":"2011","unstructured":"Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17(Suppl 2):S34\u201343","journal-title":"Liver Transpl"},{"key":"9799_CR252","doi-asserted-by":"crossref","unstructured":"Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30\u201350","DOI":"10.1148\/radiol.14132362"},{"key":"9799_CR253","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/lt.21999","volume":"16","author":"EA Pomfret","year":"2010","unstructured":"Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262\u2013278","journal-title":"Liver Transpl"},{"key":"9799_CR254","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1148\/radiol.2522081414","volume":"252","author":"A Kitao","year":"2009","unstructured":"Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at ct during arterial portography and hepatic arteriography\u2013radiologic-pathologic correlation. Radiology 2009;252:605\u2013614","journal-title":"Radiology"},{"key":"9799_CR255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000078478","volume":"47","author":"O Matsui","year":"2004","unstructured":"Matsui O. Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 2004;47:271\u2013276","journal-title":"Intervirology"},{"key":"9799_CR256","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2003.10.008","volume":"40","author":"SR Vavricka","year":"2004","unstructured":"Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 2004;40:212\u2013218","journal-title":"J Hepatol"},{"key":"9799_CR257","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1007\/s00330-011-2165-8","volume":"21","author":"A Kitao","year":"2011","unstructured":"Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21:2056\u20132066","journal-title":"Eur Radiol"},{"key":"9799_CR258","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00330-010-1812-9","volume":"20","author":"S Kogita","year":"2010","unstructured":"Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405\u20132413","journal-title":"Eur Radiol"},{"key":"9799_CR259","unstructured":"American College of Radiology. Liver imaging reporting and data system http:\/\/www.Acr.Org\/quality-safety\/resources\/lirads\/ . Accessed 16 April 2017"},{"key":"9799_CR260","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2214\/AJR.05.0257","volume":"187","author":"MJ Kim","year":"2006","unstructured":"Kim MJ, Choi JY, Lim JS, Kim JY, Kim JH, Oh YT, et al. Optimal scan window for detection of hypervascular hepatocellular carcinomas during MDCT examination. AJR Am J Roentgenol 2006;187:198\u2013206","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR261","doi-asserted-by":"crossref","first-page":"W25","DOI":"10.2214\/AJR.04.1878","volume":"187","author":"S Goshima","year":"2006","unstructured":"Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Nishibori H, et al. MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scan delays for bolus-tracking techniques of hepatic arterial and portal venous phases. AJR Am J Roentgenol 2006;187:W25\u2013W32","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR262","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2214\/AJR.07.2676","volume":"190","author":"MK Hatfield","year":"2008","unstructured":"Hatfield MK, Beres RA, Sane SS, Zaleski GX. Percutaneous imaging-guided solid organ core needle biopsy: coaxial versus noncoaxial method. AJR Am J Roentgenol 2008;190:413\u2013417","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR263","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21966","volume":"47","author":"A Forner","year":"2008","unstructured":"Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20\u00a0mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97\u2013104","journal-title":"Hepatology"},{"key":"9799_CR264","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1148\/radiol.11101549","volume":"259","author":"TK Kim","year":"2011","unstructured":"Kim TK, Lee KH, Jang HJ, Haider MA, Jacks LM, Menezes RJ, et al. Analysis of gadobenate dimeglumine-enhanced mr findings for characterizing small (1\u20132-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011;259:730\u2013738","journal-title":"Radiology"},{"key":"9799_CR265","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2012.01.004","volume":"56","author":"J Rimola","year":"2012","unstructured":"Rimola J, Forner A, Tremosini S, Reig M, Vilana R, Bianchi L, et al. Non-invasive diagnosis of hepatocellular carcinoma\u00a0\u22642\u00a0cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 2012;56:1317\u20131323","journal-title":"J Hepatol"},{"key":"9799_CR266","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/lt.20357","volume":"11","author":"JA Marrero","year":"2005","unstructured":"Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281\u2013289","journal-title":"Liver Transpl"},{"key":"9799_CR267","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1259\/bjr\/86767895","volume":"85","author":"JH Lee","year":"2012","unstructured":"Lee JH, Lee JM, Kim SJ, Baek JH, Yun SH, Kim KW, et al. Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation. Br J Radiol 2012;85:e573\u2013e583","journal-title":"Br J Radiol"},{"key":"9799_CR268","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1148\/radiol.13120775","volume":"267","author":"JW Choi","year":"2013","unstructured":"Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013;267:776\u2013786","journal-title":"Radiology"},{"key":"9799_CR269","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/gut.2009.187286","volume":"59","author":"A Sangiovanni","year":"2010","unstructured":"Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638\u2013644","journal-title":"Gut"},{"key":"9799_CR270","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","volume":"275","author":"YJ Lee","year":"2015","unstructured":"Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015;275:97\u2013109","journal-title":"Radiology"},{"key":"9799_CR271","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1097\/MD.0000000000001157","volume":"94","author":"F Ye","year":"2015","unstructured":"Ye F, Liu J, Ouyang H. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e1157","journal-title":"Medicine (Baltimore)"},{"key":"9799_CR272","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.1840380430","volume":"38","author":"M Burrel","year":"2003","unstructured":"Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003;38:1034\u20131042","journal-title":"Hepatology"},{"key":"9799_CR273","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2214\/AJR.04.1206","volume":"186","author":"YK Kim","year":"2006","unstructured":"Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Chon SB, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 2006;186:149\u2013157","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR274","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1148\/radiology.219.2.r01ma40445","volume":"219","author":"GA Krinsky","year":"2001","unstructured":"Krinsky GA, Lee VS, Theise ND, Weinreb JC, Rofsky NM, Diflo T, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219:445\u2013454","journal-title":"Radiology"},{"key":"9799_CR275","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2214\/ajr.175.3.1750693","volume":"175","author":"JH Lim","year":"2000","unstructured":"Lim JH, Kim CK, Lee WJ, Park CK, Koh KC, Paik SW, et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol 2000;175:693\u2013698","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR276","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00004728-200105000-00001","volume":"25","author":"A Rode","year":"2001","unstructured":"Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001;25:327\u2013336","journal-title":"J Comput Assist Tomogr"},{"key":"9799_CR277","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1148\/radiol.2381042193","volume":"238","author":"YK Kim","year":"2006","unstructured":"Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006;238:531\u2013541","journal-title":"Radiology"},{"key":"9799_CR278","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1148\/radiology.216.1.r00jl24154","volume":"216","author":"J Ward","year":"2000","unstructured":"Ward J, Guthrie JA, Scott DJ, Atchley J, Wilson D, Davies MH, et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000;216:154\u2013162","journal-title":"Radiology"},{"key":"9799_CR279","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/RLI.0b013e3181768d96","volume":"43","author":"HJ Yoo","year":"2008","unstructured":"Yoo HJ, Lee JM, Lee MW, Kim SJ, Lee JY, Han JK, et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation. I. Invest Radiol 2008;43:538\u2013546","journal-title":"Invest Radiol"},{"key":"9799_CR280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2214\/AJR.07.2595","volume":"190","author":"RF Hanna","year":"2008","unstructured":"Hanna RF, Kased N, Kwan SW, Gamst AC, Santosa AC, Hassanein T, et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol 2008;190:47\u201357","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR281","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1148\/rg.283055108","volume":"28","author":"RF Hanna","year":"2008","unstructured":"Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008;28:747\u2013769","journal-title":"Radiographics"},{"key":"9799_CR282","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1259\/bjr\/66686028","volume":"83","author":"G Park","year":"2010","unstructured":"Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 2010;83:1010\u20131016","journal-title":"Br J Radiol"},{"key":"9799_CR283","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiology.195.3.7754011","volume":"195","author":"B Hamm","year":"1995","unstructured":"Hamm B, Staks T, M\u00fchler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785\u2013792","journal-title":"Radiology"},{"key":"9799_CR284","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jmri.22054","volume":"31","author":"A Filippone","year":"2010","unstructured":"Filippone A, Blakeborough A, Breuer J, Grazioli L, Gschwend S, Hammerstingl R, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010;31:356\u2013364","journal-title":"J Magn Reson Imaging"},{"key":"9799_CR285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1148\/radiol.14140141","volume":"274","author":"DH Lee","year":"2015","unstructured":"Lee DH, Lee JM, Baek JH, Shin C-I, Han JK, Choi BI. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology 2015;274:149\u2013160","journal-title":"Radiology"},{"key":"9799_CR286","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1148\/radiol.12120226","volume":"265","author":"A Kitao","year":"2012","unstructured":"Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 2012;265:780\u2013789","journal-title":"Radiology"},{"key":"9799_CR287","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00330-015-3686-3","volume":"25","author":"I Joo","year":"2015","unstructured":"Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 2015;25:2859\u20132868","journal-title":"Eur Radiol"},{"key":"9799_CR288","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00261-014-0227-5","volume":"40","author":"TA Hope","year":"2015","unstructured":"Hope TA, Fowler KJ, Sirlin CB, Costa EA, Yee J, Yeh BM, et al. Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 2015;40:613\u2013625","journal-title":"Abdom Imaging"},{"key":"9799_CR289","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000367750","volume":"5","author":"I Joo","year":"2016","unstructured":"Joo I, Lee JM. Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI. Liver Cancer 2016;5:67\u201387","journal-title":"Liver Cancer"},{"key":"9799_CR290","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1148\/radiol.12112517","volume":"264","author":"MJ Park","year":"2012","unstructured":"Park MJ, Kim YK, Lee MW, Lee WJ, Kim Y-S, Kim SH, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012;264:761\u2013770","journal-title":"Radiology"},{"key":"9799_CR291","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jmri.21650","volume":"29","author":"PJ Xu","year":"2009","unstructured":"Xu PJ, Yan FH, Wang JH, Lin J, Ji Y. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging 2009;29:341\u2013349","journal-title":"J Magn Reson Imaging"},{"key":"9799_CR292","doi-asserted-by":"crossref","first-page":"e0144247","DOI":"10.1371\/journal.pone.0144247","volume":"10","author":"X Li","year":"2015","unstructured":"Li X, Li C, Wang R, Ren J, Yang J, Zhang Y. Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One 2015;10:e0144247","journal-title":"PLoS One"},{"key":"9799_CR293","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1148\/radiology.183.3.1316622","volume":"183","author":"M Kadoya","year":"1992","unstructured":"Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 1992;183:819\u2013825","journal-title":"Radiology"},{"key":"9799_CR294","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1148\/radiology.173.1.2550995","volume":"173","author":"O Matsui","year":"1989","unstructured":"Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Arai K, Gabata T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989;173:123\u2013126","journal-title":"Radiology"},{"key":"9799_CR295","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/00000478-199311000-00004","volume":"17","author":"LD Ferrell","year":"1993","unstructured":"Ferrell LD, Crawford JM, Dhillon AP, Scheuer PJ, Nakanuma Y. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993;17:1113\u20131123","journal-title":"Am J Surg Pathol"},{"key":"9799_CR296","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1016\/j.ejrad.2012.06.027","volume":"81","author":"S Kobayashi","year":"2012","unstructured":"Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, et al. Intranodular signal intensity analysis of hypovascular high-risk borderline lesions of HCC that illustrate multi-step hepatocarcinogenesis within the nodule on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 2012;81:3839\u20133845","journal-title":"Eur J Radiol"},{"key":"9799_CR297","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1016\/j.ejrad.2012.03.029","volume":"81","author":"S Kobayashi","year":"2012","unstructured":"Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, et al. Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 2012;81:3002\u20133009","journal-title":"Eur J Radiol"},{"issue":"Suppl 2","key":"9799_CR298","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1111\/j.1872-034X.2007.00176.x","volume":"37","author":"M Sakamoto","year":"2007","unstructured":"Sakamoto M. Pathology of early hepatocellular carcinoma. Hepatol Res 2007;37(Suppl 2):S135\u2013S138","journal-title":"Hepatol Res"},{"key":"9799_CR299","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0046-8177(91)90039-R","volume":"22","author":"M Sakamoto","year":"1991","unstructured":"Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172\u2013178","journal-title":"Hum Pathol"},{"key":"9799_CR300","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343865","volume":"3","author":"T Ichikawa","year":"2014","unstructured":"Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer 2014;3:97\u2013107","journal-title":"Liver Cancer"},{"key":"9799_CR301","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2214\/AJR.14.12655","volume":"205","author":"BI Choi","year":"2015","unstructured":"Choi BI, Lee JM, Kim TK, Burgio MD, Vilgrain V. Diagnosing borderline hepatic nodules in hepatocarcinogenesis: imaging performance. AJR Am J Roentgenol 2015;205:10\u201321","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR302","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00261-011-9688-y","volume":"36","author":"YN Park","year":"2011","unstructured":"Park YN, Kim MJ. Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging 2011;36:232\u2013243","journal-title":"Abdom Imaging"},{"key":"9799_CR303","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-2007-1007119","volume":"19","author":"M Kudo","year":"1999","unstructured":"Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant\/borderline lesions. Semin Liver Dis 1999;19:297\u2013309","journal-title":"Semin Liver Dis"},{"key":"9799_CR304","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1007\/s00330-008-0954-5","volume":"18","author":"R Shinmura","year":"2008","unstructured":"Shinmura R, Matsui O, Kadoya M, Kobayashi S, Terayama N, Sanada J, et al. Detection of hypervascular malignant foci in borderline lesions of hepatocellular carcinoma: comparison of dynamic multi-detector row ct, dynamic mr imaging and superparamagnetic iron oxide-enhanced mr imaging. Eur Radiol 2008;18:1918\u20131924","journal-title":"Eur Radiol"},{"key":"9799_CR305","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3348\/kjr.2008.9.4.325","volume":"9","author":"J Lee","year":"2008","unstructured":"Lee J, Lee WJ, Lim HK, Lim JH, Choi N, Park MH, et al. Early hepatocellular carcinoma: Three-phase helical ct features of 16 patients. Korean J Radiol 2008;9:325\u2013332","journal-title":"Korean J Radiol"},{"key":"9799_CR306","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejrad.2005.11.039","volume":"58","author":"K Ito","year":"2006","unstructured":"Ito K. Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 2006;58:186\u2013199","journal-title":"Eur J Radiol"},{"key":"9799_CR307","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00261-012-9952-9","volume":"38","author":"C Bartolozzi","year":"2013","unstructured":"Bartolozzi C, Battaglia V, Bargellini I, Bozzi E, Campani D, Pollina LE, et al. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 2013;38:290\u2013296","journal-title":"Abdom Imaging"},{"key":"9799_CR308","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.11101840","volume":"261","author":"K Sano","year":"2011","unstructured":"Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced mr imaging. Radiology 2011;261:834\u2013844","journal-title":"Radiology"},{"key":"9799_CR309","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000343842","volume":"2","author":"M Kudo","year":"2013","unstructured":"Kudo M. Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer 2013;2:69\u201372","journal-title":"Liver Cancer"},{"key":"9799_CR310","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.3748\/wjg.v21.i15.4583","volume":"21","author":"T Kanefuji","year":"2015","unstructured":"Kanefuji T, Takano T, Suda T, Akazawa K, Yokoo T, Kamimura H, et al. Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging. World J Gastroenterol 2015;21:4583\u20134591","journal-title":"World J Gastroenterol"},{"key":"9799_CR311","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jmri.24164","volume":"39","author":"S Ichikawa","year":"2014","unstructured":"Ichikawa S, Ichikawa T, Motosugi U, Sano K, Morisaka H, Enomoto N, et al. Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma. J Magn Reson Imaging 2014;39:293\u2013297","journal-title":"J Magn Reson Imaging"},{"key":"9799_CR312","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/RCT.0b013e3182026f3b","volume":"35","author":"S Kobayashi","year":"2011","unstructured":"Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr 2011;35:181\u2013186","journal-title":"J Comput Assist Tomogr"},{"key":"9799_CR313","first-page":"367","volume":"119","author":"E Iannicelli","year":"2014","unstructured":"Iannicelli E, Di Pietropaolo M, Marignani M, Briani C, Federici GF, Delle Fave G, et al. Gadoxetic acid-enhanced mri for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. Radiol Med 2014;119:367\u2013376","journal-title":"Radiol Med"},{"key":"9799_CR314","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/jmri.23685","volume":"36","author":"R Golfieri","year":"2012","unstructured":"Golfieri R, Grazioli L, Orlando E, Dormi A, Lucidi V, Corcioni B, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging 2012;36:648\u2013657","journal-title":"J Magn Reson Imaging"},{"key":"9799_CR315","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1159\/000368000","volume":"32","author":"JH Yoon","year":"2014","unstructured":"Yoon JH, Lee JM, Yang HK, Lee KB, Jang J-J, Han JK, et al. Non-hypervascular hypointense nodules\u00a0\u2265\u00a01\u00a0cm on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in cirrhotic livers. Dig Dis 2014;32:678\u2013689","journal-title":"Dig Dis"},{"key":"9799_CR316","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2214\/AJR.12.9136","volume":"200","author":"A Yamamoto","year":"2013","unstructured":"Yamamoto A, Ito K, Tamada T, Higaki A, Kanki A, Sato T, et al. Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI. AJR Am J Roentgenol 2013;200:1254\u20131260","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR317","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1148\/radiol.12112649","volume":"265","author":"YK Kim","year":"2012","unstructured":"Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 2012;265:104\u2013114","journal-title":"Radiology"},{"key":"9799_CR318","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1148\/radiol.12112677","volume":"266","author":"T Hyodo","year":"2013","unstructured":"Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, et al. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 2013;266:480\u2013490","journal-title":"Radiology"},{"key":"9799_CR319","doi-asserted-by":"crossref","unstructured":"Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y; Liver Cancer Study Group of Japan. Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the liver cancer study group of Japan: 2014 update. Oncology 2014;87 Suppl 1:7\u201321","DOI":"10.1159\/000368141"},{"key":"9799_CR320","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7326\/0003-4819-120-8-199404150-00008","volume":"120","author":"L Irwig","year":"1994","unstructured":"Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, Mosteller F. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994;120:667\u2013676","journal-title":"Ann Intern Med"},{"key":"9799_CR321","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1053\/jhep.2000.17914","volume":"32","author":"BJ McMahon","year":"2000","unstructured":"McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, Dunaway E, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842\u2013846","journal-title":"Hepatology"},{"key":"9799_CR322","unstructured":"Kew MC. Alpha-fetoprotein. In: Read AE, editor. Modern trends in gastroenterology. London: Butterworths; 1975. Vol. 5, p. 91"},{"key":"9799_CR323","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12072-007-9038-x","volume":"2","author":"R Tateishi","year":"2008","unstructured":"Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008;2:17\u201330","journal-title":"Hepatol Int"},{"key":"9799_CR324","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/hep.26739","volume":"59","author":"GL Wong","year":"2014","unstructured":"Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014;59:986\u2013995","journal-title":"Hepatology"},{"key":"9799_CR325","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1097\/MD.0000000000000901","volume":"94","author":"T Minami","year":"2015","unstructured":"Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, et al. Serum alpha-fetoprotein has high specificity for the early detection of hepatocellular carcinoma after hepatitis C virus eradication in patients. Medicine (Baltimore). 2015;94:e901","journal-title":"Medicine (Baltimore)"},{"key":"9799_CR326","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJM198405313102204","volume":"310","author":"HA Liebman","year":"1984","unstructured":"Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427\u20131431","journal-title":"N Engl J Med"},{"key":"9799_CR327","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N","volume":"91","author":"Y Koike","year":"2001","unstructured":"Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561\u2013569","journal-title":"Cancer"},{"key":"9799_CR328","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1046\/j.1365-2168.1999.01185.x","volume":"89","author":"H Imamura","year":"1999","unstructured":"Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999;89:1032\u20131038","journal-title":"Br J Surg"},{"key":"9799_CR329","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1111\/hepr.12201","volume":"44","author":"C Li","year":"2014","unstructured":"Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res 2014;44:E11\u2013E25","journal-title":"Hepatol Res"},{"key":"9799_CR330","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/j.1572-0241.2006.00681.x","volume":"101","author":"S Nakamura","year":"2006","unstructured":"Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038\u20132043","journal-title":"Am J Gastroenterol"},{"key":"9799_CR331","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1056\/NEJM199306243282502","volume":"328","author":"Y Sato","year":"1993","unstructured":"Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993;328:1802\u20131806","journal-title":"N Engl J Med"},{"key":"9799_CR332","first-page":"5419","volume":"53","author":"K Taketa","year":"1993","unstructured":"Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419\u20135423","journal-title":"Cancer Res"},{"key":"9799_CR333","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0167-4838(85)90277-8","volume":"830","author":"Y Aoyagi","year":"1985","unstructured":"Aoyagi Y, Isemura M, Yosizawa Z, Suzuki Y, Sekine C, Ono T, et al. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta 1985;830:217\u2013223","journal-title":"Biochim Biophys Acta"},{"key":"9799_CR334","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ab.2009.02.030","volume":"388","author":"C Kagebayashi","year":"2009","unstructured":"Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306\u2013311","journal-title":"Anal Biochem"},{"key":"9799_CR335","first-page":"5179","volume":"57","author":"HC Hsu","year":"1997","unstructured":"Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57:5179\u20135184","journal-title":"Cancer Res"},{"key":"9799_CR336","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1136\/gut.48.4.558","volume":"48","author":"ZW Zhu","year":"2001","unstructured":"Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558\u2013564","journal-title":"Gut"},{"key":"9799_CR337","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.22709","volume":"49","author":"International Consensus Group for Hepatocellular NeoplasiaThe International Consensus","year":"2009","unstructured":"International Consensus Group for Hepatocellular NeoplasiaThe International Consensus. Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658\u2013664","journal-title":"Hepatology"},{"key":"9799_CR338","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.arcmed.2014.11.002","volume":"45","author":"X Jia","year":"2014","unstructured":"Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Arch Med Res 2014;45:580\u2013588","journal-title":"Arch Med Res"},{"key":"9799_CR339","doi-asserted-by":"crossref","first-page":"e0140067","DOI":"10.1371\/journal.pone.0140067","volume":"10","author":"M Dai","year":"2015","unstructured":"Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. PLoS One 2015;10:e0140067","journal-title":"PLoS One"},{"key":"9799_CR340","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.clinre.2014.06.008","volume":"38","author":"HG Wan","year":"2014","unstructured":"Wan HG, Xu H, Gu YM, Wang H, Xu W, Zu MH. Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Clin Res Hepatol Gastroenterol 2014;38:706\u2013714","journal-title":"Clin Res Hepatol Clin Res Hepatol Gastroenterol"},{"key":"9799_CR341","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1097\/MD.0000000000000722","volume":"94","author":"W Liao","year":"2015","unstructured":"Liao W, Mao Y, Ge P, Yang H, Xu H, Lu X, Sang X, et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis. Med (Baltimore). 2015;94:e722","journal-title":"Med (Baltimore)"},{"key":"9799_CR342","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S1470-2045(15)00048-0","volume":"16","author":"XJ Lin","year":"2015","unstructured":"Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015;16:804\u2013815","journal-title":"Lancet Oncol"},{"key":"9799_CR343","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/00042737-199912000-00008","volume":"11","author":"T Sassa","year":"1999","unstructured":"Sassa T, Kumada T, Nakano S, Uematsu T. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999;11:1387\u20131392","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9799_CR344","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/jmri.24354","volume":"39","author":"L Junqiang","year":"2014","unstructured":"Junqiang L, Yinzhong W, Li Z, Shunlin G, Xiaohui W, Yanan Z, et al. Gadoxetic acid disodium (Gd-EOBDTPA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. J Magn Reson Imaging 2014;39:1079\u20131087","journal-title":"J Magn Reson Imaging"},{"key":"9799_CR345","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11604-014-0323-z","volume":"32","author":"M Matsuda","year":"2014","unstructured":"Matsuda M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, et al. Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases. Jpn J Radiol 2014;32:405\u2013413","journal-title":"Jpn J Radiol"},{"key":"9799_CR346","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0284185114534652","volume":"56","author":"KM Jang","year":"2015","unstructured":"Jang KM, Kim SH, Kim YK, Choi D. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Acta Radiol 2015;56:526\u2013535","journal-title":"Acta Radiol"},{"key":"9799_CR347","doi-asserted-by":"crossref","first-page":"641685","DOI":"10.1155\/2014\/641685","volume":"2014","author":"M Matsuda","year":"2014","unstructured":"Matsuda M, Ichikawa T, Amemiya H, Maki A, Watanabe M, Kawaida H, et al. Preoperative gadoxetic Acid-enhanced MRI and simultaneous treatment of early hepatocellular carcinoma prolonged recurrence-free survival of progressed hepatocellular carcinoma patients after hepatic resection. HPB Surg 2014;2014:641685","journal-title":"HPB Surg"},{"key":"9799_CR348","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/hep.27093","volume":"60","author":"T Yamashita","year":"2014","unstructured":"Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 2014;60:1674\u20131685","journal-title":"Hepatology"},{"key":"9799_CR349","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/liv.12550","volume":"34","author":"VY Park","year":"2014","unstructured":"Park VY, Choi JY, Chung YE, Kim H, Park MS, Lim JS, et al. Dynamic enhancement pattern of HCC smaller than 3\u00a0cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 2014;34:1593\u20131602","journal-title":"Liver Int"},{"key":"9799_CR350","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1148\/radiol.14131996","volume":"271","author":"MH Yu","year":"2014","unstructured":"Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, et al. Small (\u22641-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 2014;271:748\u2013760","journal-title":"Radiology"},{"key":"9799_CR351","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/hepr.12309","volume":"44","author":"N Komatsu","year":"2014","unstructured":"Komatsu N, Motosugi U, Maekawa S, Shindo K, Sakamoto M, Sato M, et al. Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging. Hepatol Res 2014;44:1339\u20131346","journal-title":"Hepatol Res"},{"key":"9799_CR352","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00261-013-0064-y","volume":"39","author":"KA Kim","year":"2014","unstructured":"Kim KA, Kim MJ, Choi JY, Park MS, Lim JS, Chung YE, et al. Detection of recurrent hepatocellular carcinoma on post-operative surveillance: comparison of MDCT and gadoxetic acid-enhanced MRI. Abdom Imaging 2014;39:291\u2013299","journal-title":"Abdom Imaging"},{"key":"9799_CR353","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.3748\/wjg.v19.i45.8357","volume":"19","author":"S Phongkitkarun","year":"2013","unstructured":"Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol 2013;19:8357\u20138365","journal-title":"World J Gastroenterol"},{"key":"9799_CR354","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/1751-2980.12119","volume":"15","author":"XT Zhao","year":"2014","unstructured":"Zhao XT, Li WX, Chai WM, Chen KM. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: is the addition of diffusion-weighted MRI at 3.0T beneficial? J Dig Dis 2014;15:137\u2013145","journal-title":"J Dig Dis"},{"key":"9799_CR355","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000355248","volume":"31","author":"T Inoue","year":"2013","unstructured":"Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, et al. Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors. Dig Dis 2013;31:472\u2013479","journal-title":"Dig Dis"},{"key":"9799_CR356","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jhep.2013.01.030","volume":"58","author":"H Toyoda","year":"2013","unstructured":"Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, et al. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol 2013;58:1174\u20131180","journal-title":"J Hepatol"},{"key":"9799_CR357","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.mri.2012.10.028","volume":"31","author":"Y Ooka","year":"2013","unstructured":"Ooka Y, Kanai F, Okabe S, Ueda T, Shimofusa R, Ogasawara S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging 2013;31:748\u2013754","journal-title":"Magn Reson Imaging"},{"key":"9799_CR358","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s00330-012-2685-x","volume":"23","author":"C An","year":"2013","unstructured":"An C, Park MS, Kim D, Kim YE, Chung WS, Rhee H, et al. Added value of subtraction imaging in detecting arterial enhancement in small (<3\u00a0cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol 2013;23:924\u2013930","journal-title":"Eur Radiol"},{"key":"9799_CR359","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000339018","volume":"1","author":"JM Lee","year":"2012","unstructured":"Lee JM, Yoon JH, Joo I, Woo HS. Recent advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer 2012;1:22\u201340","journal-title":"Liver Cancer"},{"key":"9799_CR360","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00535-012-0571-6","volume":"47","author":"T Inoue","year":"2012","unstructured":"Inoue T, Kudo M, Komuta M, Hayaishi S, Ueda T, Takita M, et al. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012;47:1036\u20131047","journal-title":"J Gastroenterol"},{"key":"9799_CR361","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1440-1746.2011.06988.x","volume":"27","author":"Y Eso","year":"2012","unstructured":"Eso Y, Marusawa H, Osaki Y. Education and imaging. Hepatobiliary and pancreatic: detection of early hepatocellular carcinoma by enhanced magnetic resonance imaging. J Gastroenterol Hepatol 2012;27:416","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"9799_CR362","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000333264","volume":"81","author":"A Alaboudy","year":"2011","unstructured":"Alaboudy A, Inoue T, Hatanaka K, Chung H, Hyodo T, Kumano S, et al. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid\u00ae-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography. Oncology 2011;81(Suppl 1):66\u201372","journal-title":"Oncology"},{"key":"9799_CR363","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00330-010-2030-1","volume":"21","author":"R Golfieri","year":"2011","unstructured":"Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (\u22642\u00a0cm) HCC in cirrhosis. Eur Radiol 2011;21:1233\u20131242","journal-title":"Eur Radiol"},{"key":"9799_CR364","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000339020","volume":"1","author":"J Ricke","year":"2012","unstructured":"Ricke J, Seidensticker M, Mohnike K. Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging. Liver Cancer 2012;1:51\u201358","journal-title":"Liver Cancer"},{"key":"9799_CR365","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000343833","volume":"1","author":"S Bota","year":"2012","unstructured":"Bota S, Piscaglia F, Marinelli S, Pecorelli A, Terzi E, Bolondi L. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer 2012;1:190\u2013200","journal-title":"Liver Cancer"},{"key":"9799_CR366","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000343875","volume":"3","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458\u2013468","journal-title":"Liver Cancer"},{"key":"9799_CR367","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jjco\/28.10.604","volume":"28","author":"M Sakamoto","year":"1998","unstructured":"Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6\u00a0months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1998;28:604\u2013608","journal-title":"Jpn J Clin Oncol"},{"key":"9799_CR368","volume-title":"Liver Cancer","author":"M Kojiro","year":"1997","unstructured":"Kojiro M. Pathology of hepatocellular carcinoma. In: Okuda K, Tabor E, editors. Liver Cancer. New York: Churchill Livingstone; 1997"},{"key":"9799_CR369","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2214\/ajr.178.4.1780885","volume":"178","author":"T Tajima","year":"2002","unstructured":"Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: cT angiography and pathologic correlation. AJR Am J Roentgenol 2002;178:885\u2013897","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR370","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1148\/radiol.2251011298","volume":"225","author":"M Hayashi","year":"2002","unstructured":"Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225:143\u2013149","journal-title":"Radiology"},{"issue":"Suppl 1","key":"9799_CR371","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000315229","volume":"78","author":"M Kudo","year":"2010","unstructured":"Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010;78(Suppl 1):40\u201345","journal-title":"Oncology"},{"key":"9799_CR372","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00535-014-0947-x","volume":"50","author":"T Tada","year":"2015","unstructured":"Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Okuda S, et al. Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography. J Gastroenterol 2015;50:85\u201394","journal-title":"J Gastroenterol"},{"key":"9799_CR373","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2463\/mrms.2012-0097","volume":"12","author":"D Joishi","year":"2013","unstructured":"Joishi D, Ueno A, Tanimoto A, Okuda S, Masugi Y, Emoto K, et al. Natural course of hypovascular nodules detected on gadoxetic acid-enhanced MR imaging: presence of fat is a risk factor for hypervascularization. Magn Reson Med Sci 2013;12:281\u2013287","journal-title":"Magn Reson Med Sci"},{"key":"9799_CR374","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1148\/radiol.13122186","volume":"267","author":"U Motosugi","year":"2013","unstructured":"Motosugi U. Hypovascular hypointense nodules on hepatocyte phase gadoxetic acid-enhanced MR images: too early or too progressed to determine hypervascularity. Radiology 2013;267:317\u2013318","journal-title":"Radiology"},{"key":"9799_CR375","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11604-012-0120-5","volume":"30","author":"M Takechi","year":"2012","unstructured":"Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, et al. Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol 2012;30:743\u2013751","journal-title":"Jpn J Radiol"},{"key":"9799_CR376","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.ejrad.2012.05.008","volume":"81","author":"Y Takayama","year":"2012","unstructured":"Takayama Y, Nishie A, Nakayama T, Asayama Y, Ishigami K, Kakihara D, et al. Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. Eur J Radiol 2012;81:3072\u20133078","journal-title":"Eur J Radiol"},{"key":"9799_CR377","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.ejrad.2012.01.007","volume":"81","author":"H Akai","year":"2012","unstructured":"Akai H, Matsuda I, Kiryu S, Tajima T, Takao H, Watanabe Y, et al. Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J Radiol 2012;81:2973\u20132977","journal-title":"Eur J Radiol"},{"key":"9799_CR378","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jmri.22630","volume":"34","author":"U Motosugi","year":"2011","unstructured":"Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011;34:88\u201394","journal-title":"J Magn Reson Imaging"},{"key":"9799_CR379","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2214\/AJR.10.5390","volume":"197","author":"T Kumada","year":"2011","unstructured":"Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011;197:58\u201363","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR380","first-page":"473","volume":"146","author":"A Laupacis","year":"1992","unstructured":"Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473\u2013481","journal-title":"CMAJ"},{"key":"9799_CR381","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12072-009-9145-y","volume":"3","author":"T Sato","year":"2009","unstructured":"Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009;3:544\u2013550","journal-title":"Hepatol Int"},{"key":"9799_CR382","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2005.03.019","volume":"43","author":"AM Bisceglie Di","year":"2005","unstructured":"Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005;43:434\u2013441","journal-title":"J Hepatol"},{"key":"9799_CR383","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","volume":"69","author":"Y Hoshida","year":"2009","unstructured":"Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385\u20137392","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"9799_CR384","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000111717","volume":"72","author":"SB Paul","year":"2007","unstructured":"Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007;72(Suppl 1):117\u2013123","journal-title":"Oncology"},{"key":"9799_CR385","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0168-8278(99)80016-6","volume":"30","author":"T Kumada","year":"1999","unstructured":"Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999;30:125\u2013130","journal-title":"J Hepatol"},{"key":"9799_CR386","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.gastro.2009.10.031","volume":"138","author":"AS Lok","year":"2010","unstructured":"Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493\u2013502","journal-title":"Gastroenterology"},{"key":"9799_CR387","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1111\/j.1572-0241.2007.01405.x","volume":"102","author":"RK Sterling","year":"2007","unstructured":"Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007;102:2196\u20132205","journal-title":"Am J Gastroenterol"},{"key":"9799_CR388","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ajg.2015.100","volume":"110","author":"TS Chang","year":"2015","unstructured":"Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol 2015;110:836\u2013844","journal-title":"Am J Gastroenterol"},{"key":"9799_CR389","first-page":"417","volume":"130","author":"BH Zhang","year":"2004","unstructured":"Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417\u2013422","journal-title":"J Cancer Res Clin Oncol"},{"key":"9799_CR390","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1365-2036.2004.01963.x","volume":"19","author":"OS Lin","year":"2004","unstructured":"Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004;19:1159\u20131172","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR391","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-3565(04)00443-4","volume":"3","author":"D Patel","year":"2005","unstructured":"Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75\u201384","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9799_CR392","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","volume":"6","author":"KL Andersson","year":"2008","unstructured":"Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418\u20131424","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9799_CR393","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","volume":"54","author":"JC Trinchet","year":"2011","unstructured":"Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987\u20131997","journal-title":"Hepatology"},{"key":"9799_CR394","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1756283X10385964","volume":"4","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol 2011;4:5\u201310","journal-title":"Therap Adv Gastroenterol"},{"key":"9799_CR395","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9343(96)00197-0","volume":"101","author":"FP Sarasin","year":"1996","unstructured":"Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422\u2013434","journal-title":"Am J Med"},{"key":"9799_CR396","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35\u2013S50","journal-title":"Gastroenterology"},{"key":"9799_CR397","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.21176","volume":"43","author":"A Sangiovanni","year":"2006","unstructured":"Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303\u20131310","journal-title":"Hepatology"},{"key":"9799_CR398","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1572-0241.2007.01395.x","volume":"102","author":"F Trevisani","year":"2007","unstructured":"Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnu L, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\/advanced cirrhosis? Am J Gastroenterol 2007;102:2448\u20132457","journal-title":"Am J Gastroenterol"},{"key":"9799_CR399","doi-asserted-by":"crossref","unstructured":"Jepsen P, Ott P, Andersen PK, S\u00f8rensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012;156:841\u2013847, W295","DOI":"10.7326\/0003-4819-156-12-201206190-00004"},{"key":"9799_CR400","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","volume":"136","author":"AS Lok","year":"2009","unstructured":"Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138\u2013148","journal-title":"Gastroenterology"},{"key":"9799_CR401","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.24013","volume":"53","author":"SM Martinez","year":"2011","unstructured":"Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011;53:325\u2013335","journal-title":"Hepatology"},{"key":"9799_CR402","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2014.02.022","volume":"61","author":"CF Huang","year":"2014","unstructured":"Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol 2014;61:67\u201374","journal-title":"J Hepatol"},{"key":"9799_CR403","doi-asserted-by":"crossref","first-page":"e4157","DOI":"10.1097\/MD.0000000000004157","volume":"95","author":"CF Huang","year":"2016","unstructured":"Huang CF, Yeh ML, Huang CY, Tsai PC, Ko YM, Chen KY, et al. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Med (Baltimore). 2016;95:e4157","journal-title":"Med (Baltimore)"},{"key":"9799_CR404","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3748\/wjg.v21.i4.1189","volume":"21","author":"C Leung","year":"2015","unstructured":"Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015;21:1189\u20131196","journal-title":"World J Gastroenterol"},{"key":"9799_CR405","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","volume":"45","author":"S Bruno","year":"2007","unstructured":"Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579\u2013587","journal-title":"Hepatology"},{"key":"9799_CR406","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","volume":"28","author":"JJ Sung","year":"2008","unstructured":"Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067\u20131077","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR407","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1478-3231.2012.02792.x","volume":"32","author":"P Song","year":"2012","unstructured":"Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int 2012;32:1053\u20131063","journal-title":"Liver Int"},{"key":"9799_CR408","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/gutjnl-2013-306627","volume":"63","author":"J Bruix","year":"2014","unstructured":"Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844\u2013855","journal-title":"Gut"},{"key":"9799_CR409","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology 2016;150:835\u2013853","journal-title":"Gastroenterology"},{"key":"9799_CR410","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/SLA.0b013e31828329b8","volume":"257","author":"G Torzilli","year":"2013","unstructured":"Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL\/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013;257:929\u2013937","journal-title":"Ann Surg"},{"issue":"Suppl 1","key":"9799_CR411","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000333280","volume":"81","author":"KH Han","year":"2011","unstructured":"Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011;81(Suppl 1):158\u2013164","journal-title":"Oncology"},{"key":"9799_CR412","doi-asserted-by":"crossref","unstructured":"Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015;45","DOI":"10.1111\/hepr.12464"},{"key":"9799_CR413","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1159\/000439101","volume":"33","author":"M Kudo","year":"2015","unstructured":"Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the Outstanding Achievements of the Liver Cancer Study Group of Japan. Dig Dis 2015;33:765\u2013770","journal-title":"Dig Dis"},{"key":"9799_CR414","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","volume":"146","author":"T Yau","year":"2014","unstructured":"Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146:1691\u20131700","journal-title":"Gastroenterology"},{"key":"9799_CR415","first-page":"267","volume":"9","author":"Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC)","year":"2014","unstructured":"Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver 2014;9:267\u2013317","journal-title":"Gut Liver"},{"key":"9799_CR416","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693\u2013699","journal-title":"N Engl J Med"},{"key":"9799_CR417","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","volume":"33","author":"FY Yao","year":"2001","unstructured":"Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394\u20131403","journal-title":"Hepatology"},{"key":"9799_CR418","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1111\/ajt.12923","volume":"14","author":"C Toso","year":"2014","unstructured":"Toso C, Mazzaferro V, Bruix J, Freeman R, Mentha G, Majno P. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant 2014;14:2221\u20132227","journal-title":"Am J Transplant"},{"key":"9799_CR419","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","volume":"13","author":"PA Clavien","year":"2012","unstructured":"Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11\u2013e22","journal-title":"Lancet Oncol"},{"key":"9799_CR420","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1600-6143.2007.02138.x","volume":"8","author":"ML Volk","year":"2008","unstructured":"Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839\u2013846","journal-title":"Am J Transplant"},{"key":"9799_CR421","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000343866","volume":"3","author":"N Akamatsu","year":"2014","unstructured":"Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer 2014;3:108\u2013118","journal-title":"Liver Cancer"},{"key":"9799_CR422","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1600-6143.2007.01802.x","volume":"7","author":"RA Fisher","year":"2007","unstructured":"Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transpl 2007;7:1601\u20131608","journal-title":"Am J Transpl"},{"key":"9799_CR423","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/lt.23490","volume":"18","author":"W Liang","year":"2012","unstructured":"Liang W, Wu L, Ling X, Schroder PM, Ju W, Wang D, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:1226\u20131236","journal-title":"Liver Transpl"},{"key":"9799_CR424","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","volume":"65","author":"X Xu","year":"2016","unstructured":"Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut 2016;65:1035\u20131041","journal-title":"Gut"},{"key":"9799_CR425","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(11)70144-9","volume":"12","author":"A Vitale","year":"2011","unstructured":"Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011;12:654\u2013662","journal-title":"Lancet Oncol"},{"key":"9799_CR426","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2012.11.009","volume":"58","author":"K Hasegawa","year":"2013","unstructured":"Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013;58:724\u2013729","journal-title":"J Hepatol"},{"key":"9799_CR427","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jamcollsurg.2012.04.013","volume":"215","author":"F Giuliante","year":"2012","unstructured":"Giuliante F, Ardito F, Pinna AD, Sarno G, Giulini SM, Ercolani G, et al. Liver resection for hepatocellular carcinoma \u22643\u00a0cm: results of an Italian multicenter study on 588 patients. J Am Coll Surg 2012;215:244\u2013254","journal-title":"J Am Coll Surg"},{"key":"9799_CR428","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/hep.27321","volume":"61","author":"A Cucchetti","year":"2015","unstructured":"Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, et al. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology 2015;61:905\u2013914","journal-title":"Hepatology"},{"key":"9799_CR429","doi-asserted-by":"crossref","unstructured":"Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, et al. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398\u2013404","DOI":"10.1111\/j.1477-2574.2009.00073.x"},{"key":"9799_CR430","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1477-2574.2012.00594.x","volume":"15","author":"R Santambrogio","year":"2013","unstructured":"Santambrogio R, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh\u2019s A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB (Oxford). 2013;15:78\u201384","journal-title":"HPB (Oxford)"},{"key":"9799_CR431","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejso.2012.12.011","volume":"39","author":"MF Silva","year":"2013","unstructured":"Silva MF, Sapisochin G, Strasser SI, Hewa-Geeganage S, Chen J, Wigg AJ, et al. Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5\u00a0cm: a multicenter, exploratory analysis. Eur J Surg Oncol 2013;39:386\u2013395","journal-title":"Eur J Surg Oncol"},{"key":"9799_CR432","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/COC.0b013e318209ab7d","volume":"35","author":"TC Chua","year":"2012","unstructured":"Chua TC, Saxena A, Chu F, Morris DL. Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria. Am J Clin Oncol 2012;35:141\u2013145","journal-title":"Am J Clin Oncol"},{"key":"9799_CR433","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00268-011-1000-3","volume":"35","author":"F Muscari","year":"2011","unstructured":"Muscari F, Foppa B, Carrere N, Kamar N, Peron JM, Suc B. Resection of a transplantable single-nodule hepatocellular carcinoma in Child-Pugh class A cirrhosis: factors affecting survival and recurrence. World J Surg 2011;35:1055\u20131062","journal-title":"World J Surg"},{"key":"9799_CR434","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jamcollsurg.2014.12.030","volume":"220","author":"WC Chapman","year":"2015","unstructured":"Chapman WC, Klintmalm G, Hemming A, Vachharajani N, Majella Doyle MB, DeMatteo R, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg 2015;220:628\u2013637","journal-title":"J Am Coll Surg"},{"key":"9799_CR435","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/SLA.0b013e318273bad0","volume":"256","author":"R Adam","year":"2012","unstructured":"Adam R, Bhangui P, Vibert E, Azoulay D, Pelletier G, Duclos-Vallee JC, et al. Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg 2012;256:883\u2013891","journal-title":"Ann Surg"},{"key":"9799_CR436","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1245\/s10434-014-4099-2","volume":"22","author":"A Vitale","year":"2015","unstructured":"Vitale A, Huo TL, Cucchetti A, Lee YH, Volk M, Frigo AC, et al. Survival benefit of liver transplantation versus resection for hepatocellular carcinoma: impact of MELD score. Ann Surg Oncol 2015;22:1901\u20131907","journal-title":"Ann Surg Oncol"},{"key":"9799_CR437","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1245\/s10434-014-3808-1","volume":"21","author":"A Proneth","year":"2014","unstructured":"Proneth A, Zeman F, Schlitt HJ, Schnitzbauer AA. Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis. Ann Surg Oncol 2014;21:3096\u20133107","journal-title":"Ann Surg Oncol"},{"key":"9799_CR438","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.sla.0000098621.74851.65","volume":"238","author":"J Belghiti","year":"2003","unstructured":"Belghiti J, Cortes A, Abdalla EK, R\u00e9gimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003;238:885\u2013892","journal-title":"Ann Surg"},{"key":"9799_CR439","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/SLA.0000000000001442","volume":"264","author":"P Bhangui","year":"2016","unstructured":"Bhangui P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, et al. salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg 2016;264:155\u2013163","journal-title":"Ann Surg"},{"key":"9799_CR440","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","volume":"134","author":"T Ishizawa","year":"2008","unstructured":"Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908\u20131916","journal-title":"Gastroenterology"},{"key":"9799_CR441","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2015.10.015","volume":"64","author":"J Shindoh","year":"2016","unstructured":"Shindoh J, Makuuchi M, Matsuyama Y, Mise Y, Arita J, Sakamoto Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol 2016;64:594\u2013600","journal-title":"J Hepatol"},{"key":"9799_CR442","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/bjs.8915","volume":"99","author":"KC Lim","year":"2012","unstructured":"Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 2012;99:1622\u20131629","journal-title":"Br J Surg"},{"key":"9799_CR443","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ssu.2980090404","volume":"9","author":"M Makuuchi","year":"1993","unstructured":"Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol 1993;9:298\u2013304","journal-title":"Semin Surg Oncol"},{"key":"9799_CR444","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/archsurg.134.9.984","volume":"134","author":"G Torzilli","year":"1999","unstructured":"Torzilli G, Makuuchi M, Inoue K, Takayama T, Sakamoto Y, Sugawara Y, et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999;134:984\u2013992","journal-title":"Arch Surg"},{"key":"9799_CR445","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/bjs.1800840917","volume":"84","author":"H Lau","year":"1997","unstructured":"Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997;84:1255\u20131259","journal-title":"Br J Surg"},{"key":"9799_CR446","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00268-005-0383-4","volume":"30","author":"T Kamiyama","year":"2006","unstructured":"Kamiyama T, Nakagawa T, Nakanishi K, Kamachi H, Onodera Y, Matsushita M, et al. Preoperative evaluation of hepatic vasculature by three-dimensional computed tomography in patients undergoing hepatectomy. World J Surg 2006;30:400\u2013409","journal-title":"World J Surg"},{"key":"9799_CR447","first-page":"521","volume":"107","author":"M Makuuchi","year":"1990","unstructured":"Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunv\u00e9n P, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990;107:521\u2013527","journal-title":"Surgery"},{"key":"9799_CR448","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00535-012-0569-0","volume":"47","author":"M Sato","year":"2012","unstructured":"Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S, et al. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 2012;47:1125\u20131133","journal-title":"J Gastroenterol"},{"key":"9799_CR449","doi-asserted-by":"crossref","unstructured":"Sugiura N, Takara K, Ohto M, Okuda K, Hirooka N. Ultrasound image-guided percutaneous intratumor ethanol injection for small hepatocellular carcinoma. Acta Hepatol Jpn 1983; 24:920 (Japanese)","DOI":"10.2957\/kanzo.24.920"},{"key":"9799_CR450","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1148\/radiology.161.2.3020612","volume":"161","author":"T Livraghi","year":"1986","unstructured":"Livraghi T, Festi D, Monti F, Salmi A, Vettori C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 1986;161:309\u2013312","journal-title":"Radiology"},{"key":"9799_CR451","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2214\/ajr.149.5.949","volume":"149","author":"S Shiina","year":"1987","unstructured":"Shiina S, Yasuda H, Muto H, Tagawa K, Unuma T, Ibukuro K, et al. Percutaneous ethanol injection in the treatment of liver neoplasms. AJR Am J Roentgenol 1987;149:949\u2013952","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR452","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/1097-0142(19940801)74:3<817::AID-CNCR2820740306>3.0.CO;2-8","volume":"74","author":"T Seki","year":"1994","unstructured":"Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994;74:817\u2013825","journal-title":"Cancer"},{"key":"9799_CR453","first-page":"73","volume":"1","author":"S Rossi","year":"1995","unstructured":"Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995;1:73\u201381","journal-title":"Cancer J Sci Am"},{"key":"9799_CR454","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1148\/radiology.210.3.r99fe40655","volume":"210","author":"T Livraghi","year":"1999","unstructured":"Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655\u2013661","journal-title":"Radiology"},{"key":"9799_CR455","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","volume":"129","author":"S Shiina","year":"2005","unstructured":"Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122\u2013130","journal-title":"Gastroenterology"},{"key":"9799_CR456","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2005.03.033","volume":"43","author":"M Ebara","year":"2005","unstructured":"Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005;43:458\u2013464","journal-title":"J Hepatol"},{"key":"9799_CR457","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2214\/ajr.160.5.7682378","volume":"160","author":"S Shiina","year":"1993","unstructured":"Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol 1993;160:1023\u20131028","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR458","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3348\/kjr.2006.7.3.187","volume":"7","author":"YM Sung","year":"2006","unstructured":"Sung YM, Choi D, Lim HK, Lee WJ, Kim SH, Kim MJ, et al. Long-term results of percutaneous ethanol injection for the treatment of hepatocellular carcinoma in Korea. Korean J Radiol 2006;7:187\u2013192","journal-title":"Korean J Radiol"},{"key":"9799_CR459","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1478-3231.2012.02838.x","volume":"32","author":"S Shiina","year":"2012","unstructured":"Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int 2012;32:1434\u20131442","journal-title":"Liver Int"},{"key":"9799_CR460","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1148\/radiology.197.1.7568806","volume":"197","author":"T Livraghi","year":"1995","unstructured":"Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101\u2013108","journal-title":"Radiology"},{"key":"9799_CR461","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1792::AID-CNCR6>3.0.CO;2-E","volume":"77","author":"H Ishii","year":"1996","unstructured":"Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996;77:1792\u20131796","journal-title":"Cancer"},{"key":"9799_CR462","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3109\/00365529709002998","volume":"32","author":"M Stasi Di","year":"1997","unstructured":"Di Stasi M, Buscarini L, Livraghi T, Giorgio A, Salmi A, De Sio I, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 1997;32:1168\u20131173","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 1","key":"9799_CR463","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000048278","volume":"62","author":"S Shiina","year":"2002","unstructured":"Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002;62(Suppl 1):64\u201368","journal-title":"Oncology"},{"key":"9799_CR464","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.jvir.2010.04.007","volume":"21","author":"MG Lubner","year":"2010","unstructured":"Lubner MG, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010;21:S192\u2013S203","journal-title":"J Vasc Interv Radiol"},{"key":"9799_CR465","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2343040350","volume":"234","author":"R Lencioni","year":"2005","unstructured":"Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961\u2013967","journal-title":"Radiology"},{"key":"9799_CR466","doi-asserted-by":"crossref","unstructured":"Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201\u20131209","DOI":"10.1002\/cncr.20892"},{"key":"9799_CR467","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","volume":"47","author":"T Livraghi","year":"2008","unstructured":"Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82\u201389","journal-title":"Hepatology"},{"key":"9799_CR468","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejrad.2007.07.007","volume":"67","author":"K Yan","year":"2008","unstructured":"Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol 2008;67:336\u2013347","journal-title":"Eur J Radiol"},{"key":"9799_CR469","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ajg.2011.425","volume":"107","author":"S Shiina","year":"2012","unstructured":"Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569\u2013577","journal-title":"Am J Gastroenterol"},{"key":"9799_CR470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2012.09.020","volume":"58","author":"YS Kim","year":"2013","unstructured":"Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013;58:89\u201397","journal-title":"J Hepatol"},{"key":"9799_CR471","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2214\/ajr.181.4.1810997","volume":"181","author":"M Kitamoto","year":"2003","unstructured":"Kitamoto M, Imagawa M, Yamada H, Watanabe C, Sumioka M, Satoh O, et al. Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol 2003;181:997\u20131003","journal-title":"AJR Am J Roentgenol"},{"key":"9799_CR472","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1002\/cncr.25314","volume":"116","author":"M Morimoto","year":"2010","unstructured":"Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010;116:5452\u20135460","journal-title":"Cancer"},{"key":"9799_CR473","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3904\/kjim.2015.112","volume":"31","author":"MJ Song","year":"2016","unstructured":"Song MJ, Bae SH, Lee JS, Lee SW, Lee SW, do Song S, You CR, et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med 2016;31:242\u2013252","journal-title":"Korean J Intern Med"},{"key":"9799_CR474","doi-asserted-by":"crossref","first-page":"e89081","DOI":"10.1371\/journal.pone.0089081","volume":"9","author":"H Xie","year":"2014","unstructured":"Xie H, Wang H, An W, Ma W, Qi R, Yang B, et al. The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. PLoS One 2014;9:e89081","journal-title":"PLoS One"},{"key":"9799_CR475","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1478-3231.2006.01434.x","volume":"27","author":"M Kobayashi","year":"2007","unstructured":"Kobayashi M, Ikeda K, Kawamura Y, Hosaka T, Sezaki H, Yatsuji H, et al. Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma\u2013direct ablative effects and a long-term outcome. Liver Int 2007;27:353\u2013359","journal-title":"Liver Int"},{"key":"9799_CR476","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jvir.2014.01.028","volume":"25","author":"HJ Scheffer","year":"2014","unstructured":"Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 2014;25:997\u20131011","journal-title":"J Vasc Interv Radiol"},{"key":"9799_CR477","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1148\/radiol.2281020718","volume":"228","author":"RA Lencioni","year":"2003","unstructured":"Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235\u2013240","journal-title":"Radiology"},{"key":"9799_CR478","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2004.09.003","volume":"127","author":"SM Lin","year":"2004","unstructured":"Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma\u00a0<\u00a0or\u00a0=\u00a04 cm. Gastroenterology 2004;127:1714\u20131723","journal-title":"Gastroenterology"},{"key":"9799_CR479","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/gut.2004.045203","volume":"54","author":"SM Lin","year":"2005","unstructured":"Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3\u00a0cm or less. Gut 2005;54:1151\u20131156","journal-title":"Gut"},{"key":"9799_CR480","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/00365520701885481","volume":"43","author":"F Brunello","year":"2008","unstructured":"Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008;43:727\u2013735","journal-title":"Scand J Gastroenterol"},{"key":"9799_CR481","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1148\/radiol.2232010775","volume":"223","author":"T Shibata","year":"2002","unstructured":"Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002;223:331\u2013337","journal-title":"Radiology"},{"key":"9799_CR482","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","volume":"243","author":"MS Chen","year":"2006","unstructured":"Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321\u2013328","journal-title":"Ann Surg"},{"key":"9799_CR483","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","volume":"57","author":"K Feng","year":"2012","unstructured":"Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794\u2013802","journal-title":"J Hepatol"},{"key":"9799_CR484","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/jgh.12441","volume":"29","author":"Y Fang","year":"2014","unstructured":"Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:193\u2013200","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR485","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","volume":"252","author":"J Huang","year":"2010","unstructured":"Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903\u2013912","journal-title":"Ann Surg"},{"key":"9799_CR486","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.mcg.0000152746.72149.31","volume":"39","author":"SN Hong","year":"2005","unstructured":"Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005;39:247\u2013252","journal-title":"J Clin Gastroenterol"},{"key":"9799_CR487","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1440-1746.2007.05262.x","volume":"23","author":"K Yamagiwa","year":"2008","unstructured":"Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, et al. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J Gastroenterol Hepatol 2008;23:482\u2013490","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR488","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1148\/radiol.2471070818","volume":"247","author":"K Yamakado","year":"2008","unstructured":"Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008;247:260\u2013266","journal-title":"Radiology"},{"key":"9799_CR489","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/bjs.9960","volume":"103","author":"GA Kim","year":"2016","unstructured":"Kim GA, Shim JH, Kim MJ, Kim SY, Won HJ, Shin YM, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. Br J Surg 2016;103:126\u2013135","journal-title":"Br J Surg"},{"key":"9799_CR490","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jamcollsurg.2015.08.009","volume":"221","author":"L Jiang","year":"2015","unstructured":"Jiang L, Yan L, Wen T, Li B, Zeng Y, Yang J, et al. Comparison of outcomes of hepatic resection and radiofrequency ablation for hepatocellular carcinoma patients with multifocal tumors meeting the barcelona-clinic liver cancer stage A classification. J Am Coll Surg 2015;221:951\u2013961","journal-title":"J Am Coll Surg"},{"key":"9799_CR491","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1148\/radiol.15141483","volume":"275","author":"TW Kang","year":"2015","unstructured":"Kang TW, Kim JM, Rhim H, Lee MW, Kim YS, Lim HK, et al. Small hepatocellular carcinoma: radiofrequency ablation versus nonanatomic resection-propensity score analyses of long-term outcomes. Radiology 2015;275:908\u2013919","journal-title":"Radiology"},{"key":"9799_CR492","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1148\/radiol.13131760","volume":"271","author":"HJ Yang","year":"2014","unstructured":"Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014;271:909\u2013918","journal-title":"Radiology"},{"key":"9799_CR493","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.dld.2013.10.015","volume":"46","author":"A Cucchetti","year":"2014","unstructured":"Cucchetti A, Piscaglia F, Cescon M, Serra C, Colecchia A, Maroni L, et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014;46:257\u2013263","journal-title":"Dig Liver Dis"},{"key":"9799_CR494","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MEG.0000000000000012","volume":"26","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Lei J, Li B, Yan L, Wang W, Wei Y, Cheng K. Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule\u00a0<2\u00a0cm): a single-center study. Eur J Gastroenterol Hepatol 2014;26:339\u2013344","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9799_CR495","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1477-2574.2012.00541.x","volume":"15","author":"S Tohme","year":"2013","unstructured":"Tohme S, Geller DA, Cardinal JS, Chen HW, Packiam V, Reddy S, et al. Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma. HPB (Oxford). 2013;15:210\u2013217","journal-title":"HPB (Oxford)"},{"key":"9799_CR496","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00534-009-0239-7","volume":"17","author":"T Takayama","year":"2010","unstructured":"Takayama T, Makuuchi M, Hasegawa K. Single HCC smaller than 2\u00a0cm: surgery or ablation? Surgeon\u2019s perspective. J Hepatob Pancreat Sci 2010;17:422\u2013424","journal-title":"J Hepatob Pancreat Sci"},{"key":"9799_CR497","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cgh.2010.08.018","volume":"9","author":"HH Hung","year":"2011","unstructured":"Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011;9:79\u201386","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9799_CR498","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.sla.0000129672.51886.44","volume":"240","author":"M Vivarelli","year":"2004","unstructured":"Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004;240:102\u2013107","journal-title":"Ann Surg"},{"key":"9799_CR499","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11605-007-0392-8","volume":"12","author":"A Guglielmi","year":"2008","unstructured":"Guglielmi A, Ruzzenente A, Valdegamberi A, Pachera S, Campagnaro T, D\u2019Onofrio M, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008;12:192\u2013198","journal-title":"J Gastrointest Surg"},{"key":"9799_CR500","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/00365521.2014.953572","volume":"50","author":"I Gory","year":"2015","unstructured":"Gory I, Fink M, Bell S, Gow P, Nicoll A, Knight V, et al. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol 2015;50:567\u2013576","journal-title":"Scand J Gastroenterol"},{"key":"9799_CR501","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11605-010-1372-y","volume":"15","author":"J Huang","year":"2011","unstructured":"Huang J, Hernandez-Alejandro R, Croome KP, Yan L, Wu H, Chen Z, et al. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases. J Gastrointest Surg 2011;15:311\u2013320","journal-title":"J Gastrointest Surg"},{"key":"9799_CR502","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s12072-010-9237-8","volume":"5","author":"WK Yun","year":"2011","unstructured":"Yun WK, Choi MS, Choi D, Rhim HC, Joh JW, Kim KH, et al. Superior long-term outcomes after surgery in child-pugh class A patients with single small hepatocellular carcinoma compared to radiofrequency ablation. Hepatol Int 2011;5:722\u2013729","journal-title":"Hepatol Int"},{"key":"9799_CR503","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MCG.0000000000000133","volume":"49","author":"YH Lee","year":"2015","unstructured":"Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, et al. Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: a retrospective study using propensity score analyses. J Clin Gastroenterol 2015;49:242\u2013249","journal-title":"J Clin Gastroenterol"},{"key":"9799_CR504","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2013.04.009","volume":"59","author":"A Cucchetti","year":"2013","unstructured":"Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013;59:300\u2013307","journal-title":"J Hepatol"},{"key":"9799_CR505","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1872-034X.2010.00696.x","volume":"40","author":"K Hasegawa","year":"2010","unstructured":"Hasegawa K, Kokudo N, Shiina S, Tateishi R, Makuuchi M. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: start of a randomized controlled trial (SURF trial). Hepatol Res 2010;40:851\u2013852","journal-title":"Hepatol Res"},{"key":"9799_CR506","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ultrasmedbio.2012.09.002","volume":"39","author":"M Claudon","year":"2013","unstructured":"Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nols\u00f8e CP, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver\u2014update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013;39:187\u2013210","journal-title":"Ultrasound Med Biol"},{"key":"9799_CR507","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jvir.2010.10.033","volume":"22","author":"J Kr\u00fccker","year":"2011","unstructured":"Kr\u00fccker J, Xu S, Venkatesan A, Locklin JK, Amalou H, Glossop N, et al. Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol 2011;22:515\u2013524","journal-title":"J Vasc Interv Radiol"},{"key":"9799_CR508","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-2008-1040608","volume":"6","author":"T Nakashima","year":"1986","unstructured":"Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis 1986;6:259\u2013266","journal-title":"Semin Liver Dis"},{"key":"9799_CR509","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","volume":"148","author":"R Yamada","year":"1983","unstructured":"Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397\u2013401","journal-title":"Radiology"},{"key":"9799_CR510","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.2006.09.8657","volume":"25","author":"E Liapi","year":"2007","unstructured":"Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007;25:978\u2013986","journal-title":"J Clin Oncol"},{"key":"9799_CR511","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164\u20131171","journal-title":"Hepatology"},{"key":"9799_CR512","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734\u20131739","journal-title":"Lancet"},{"key":"9799_CR513","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429\u2013442","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"9799_CR514","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","volume":"48","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20\u2013S37","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"9799_CR515","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000111702","volume":"72","author":"M Kudo","year":"2007","unstructured":"Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(Suppl 1):2\u201315","journal-title":"Oncology"},{"key":"9799_CR516","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","volume":"134","author":"HB El-Serag","year":"2008","unstructured":"El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752\u20131763","journal-title":"Gastroenterology"},{"key":"9799_CR517","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1148\/radiology.215.1.r00ap21123","volume":"215","author":"E Caturelli","year":"2000","unstructured":"Caturelli E, Siena DA, Fusilli S, Villani MR, Schiavone G, Nardella M, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000;215:123\u2013128","journal-title":"Radiology"},{"key":"9799_CR518","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/cncr.10407","volume":"94","author":"AO Chan","year":"2002","unstructured":"Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94:1747\u20131752","journal-title":"Cancer"},{"key":"9799_CR519","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1148\/radiology.198.1.8539401","volume":"198","author":"JW Chung","year":"1996","unstructured":"Chung JW, Park JH, Han JK, Choi BI, Han MC, Lee HS, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33\u201340","journal-title":"Radiology"},{"key":"9799_CR520","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/cncr.11106","volume":"97","author":"S Iwamoto","year":"2003","unstructured":"Iwamoto S, Sanefuji H, Okuda K. Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma. Cancer 2003;97:1051\u20131056","journal-title":"Cancer"},{"key":"9799_CR521","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1148\/radiology.188.1.8390073","volume":"188","author":"O Matsui","year":"1993","unstructured":"Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79\u201383","journal-title":"Radiology"},{"key":"9799_CR522","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","volume":"46","author":"M Varela","year":"2007","unstructured":"Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474\u2013481","journal-title":"J Hepatol"},{"key":"9799_CR523","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2011.05.002","volume":"38","author":"J Meza-Junco","year":"2012","unstructured":"Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, et al. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 2012;38:54\u201362","journal-title":"Cancer Treat Rev"},{"key":"9799_CR524","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41\u201352","journal-title":"Cardiovasc Intervent Radiol"},{"key":"9799_CR525","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/liv.12314","volume":"34","author":"AL Cheng","year":"2014","unstructured":"Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174\u2013183","journal-title":"Liver Int"},{"key":"9799_CR526","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jgh.13218","volume":"31","author":"S Lee","year":"2016","unstructured":"Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, et al. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: a cohort study of the multicenter registry database. J Gastroenterol Hepatol 2016;31:842\u2013847","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR527","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/liv.12865","volume":"36","author":"BK Kim","year":"2016","unstructured":"Kim BK, Shim JH, Kim SU, Park JY, do Kim Y, Ahn SH, et al. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int 2016;36:92\u201399","journal-title":"Liver Int"},{"key":"9799_CR528","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","volume":"24","author":"L Kadalayil","year":"2013","unstructured":"Kadalayil L, Benini R, Pallan L, O\u2019Beirne J, Marelli L, Yu D, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013;24:2565\u20132570","journal-title":"Ann Oncol"},{"key":"9799_CR529","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/liv.12878","volume":"36","author":"Y Park","year":"2016","unstructured":"Park Y, Kim SU, Kim BK, Park JY, do Kim Y, Ahn SH, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int 2016;36:100\u2013107","journal-title":"Liver Int"},{"key":"9799_CR530","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2014.07.002","volume":"61","author":"F Hucke","year":"2014","unstructured":"Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 2014;61:1287\u20131296","journal-title":"J Hepatol"},{"key":"9799_CR531","doi-asserted-by":"crossref","first-page":"e0125244","DOI":"10.1371\/journal.pone.0125244","volume":"10","author":"S Ogasawara","year":"2015","unstructured":"Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, et al. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. PLoS One 2015;10:e0125244","journal-title":"PLoS One"},{"key":"9799_CR532","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/hep.26256","volume":"57","author":"W Sieghart","year":"2013","unstructured":"Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57:2261\u20132273","journal-title":"Hepatology"},{"key":"9799_CR533","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35\u201343","journal-title":"Lancet Oncol"},{"key":"9799_CR534","first-page":"348","volume":"32","author":"L Bolondi","year":"2012","unstructured":"Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32:348\u2013359","journal-title":"Semin Liver Dis"},{"key":"9799_CR535","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","volume":"21","author":"ND Parikh","year":"2015","unstructured":"Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 2015;21:1142\u20131152","journal-title":"Liver Transpl"},{"key":"9799_CR536","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207\u2013214","journal-title":"Cancer"},{"key":"9799_CR537","doi-asserted-by":"crossref","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205\u2013216","DOI":"10.1093\/jnci\/92.3.205"},{"key":"9799_CR538","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ejca.2012.08.022","volume":"49","author":"BK Kim","year":"2013","unstructured":"Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, et al. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 2013;49:826\u2013834","journal-title":"Eur J Cancer"},{"key":"9799_CR539","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421\u2013430","journal-title":"J Hepatol"},{"key":"9799_CR540","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52\u201360","journal-title":"Semin Liver Dis"},{"key":"9799_CR541","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2013.01.039","volume":"58","author":"ES Jung","year":"2013","unstructured":"Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 2013;58:1181\u20131187","journal-title":"J Hepatol"},{"key":"9799_CR542","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1148\/radiol.11110282","volume":"262","author":"JH Shim","year":"2012","unstructured":"Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262:708\u2013718","journal-title":"Radiology"},{"key":"9799_CR543","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","volume":"55","author":"R Gillmore","year":"2011","unstructured":"Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309\u20131316","journal-title":"J Hepatol"},{"key":"9799_CR544","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10147-013-0634-6","volume":"19","author":"T Arai","year":"2014","unstructured":"Arai T, Kobayashi A, Ohya A, Takahashi M, Yokoyama T, Shimizu A, et al. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol 2014;19:871\u2013879","journal-title":"Int J Clin Oncol"},{"key":"9799_CR545","doi-asserted-by":"crossref","unstructured":"Lee YK, Kim SU, Kim do Y, Ahn SH, Lee KH, Lee do Y, et al. Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013;13:5","DOI":"10.1186\/1471-2407-13-5"},{"key":"9799_CR546","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","volume":"37","author":"JL Raoul","year":"2011","unstructured":"Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212\u2013220","journal-title":"Cancer Treat Rev"},{"key":"9799_CR547","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1440-1746.2011.06963.x","volume":"27","author":"HY Kim","year":"2012","unstructured":"Kim HY, Park JW, Joo J, Jung SJ, An S, Woo SM, et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1051\u20131056","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR548","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339\u2013364","journal-title":"Dig Dis"},{"key":"9799_CR549","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000365993","volume":"87","author":"S Ogasawara","year":"2014","unstructured":"Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 2014;87:330\u2013341","journal-title":"Oncology"},{"key":"9799_CR550","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000367743","volume":"4","author":"T Arizumi","year":"2015","unstructured":"Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 2015;4:253\u2013262","journal-title":"Liver Cancer"},{"key":"9799_CR551","doi-asserted-by":"crossref","unstructured":"Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 2013;33(3):327\u2013337","DOI":"10.1111\/liv.12083"},{"key":"9799_CR552","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 2016;64:1090\u20131098","journal-title":"J Hepatol"},{"key":"9799_CR553","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000367728","volume":"4","author":"RT Poon","year":"2015","unstructured":"Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, et al. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer 2015;4:51\u201369","journal-title":"Liver Cancer"},{"key":"9799_CR554","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826\u20131837","journal-title":"Hepatology"},{"key":"9799_CR555","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52\u201364","journal-title":"Gastroenterology"},{"key":"9799_CR556","doi-asserted-by":"crossref","unstructured":"Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868\u2013878","DOI":"10.1002\/hep.24451"},{"key":"9799_CR557","doi-asserted-by":"crossref","unstructured":"Kim do Y, Park BJ, Kim YH, Han KH, Cho SB, Cho KR, et al. Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol 2015;38:495\u2013501","DOI":"10.1097\/COC.0b013e3182a78dba"},{"key":"9799_CR558","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1477-2574.2010.00183.x","volume":"12","author":"RE Schwarz","year":"2010","unstructured":"Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP, et al. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12:313\u2013320","journal-title":"HPB (Oxford)"},{"key":"9799_CR559","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","volume":"111","author":"S Culleton","year":"2014","unstructured":"Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412\u2013417","journal-title":"Radiother Oncol"},{"key":"9799_CR560","doi-asserted-by":"crossref","unstructured":"Lanciano R, Lamond J, Yang J, Feng J, Arrigo S, Good M, et al. Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol 2012;2:23","DOI":"10.3389\/fonc.2012.00023"},{"key":"9799_CR561","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3857\/roj.2015.33.4.276","volume":"33","author":"SW Seol","year":"2015","unstructured":"Seol SW, Yu JI, Park HC, Lim DH, Oh D, Noh JM, et al. Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J 2015;33:276\u2013283","journal-title":"Radiat Oncol J"},{"key":"9799_CR562","doi-asserted-by":"crossref","unstructured":"Liang SX, Zhu XD, Lu HJ, Pan CY, Li FX, Huang QF, et al. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 2005;103:2181\u20132188","DOI":"10.1002\/cncr.21012"},{"key":"9799_CR563","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/COC.0b013e3181b0c298","volume":"33","author":"D Oh","year":"2010","unstructured":"Oh D, Lim DH, Park HC, Paik SW, Koh KC, Lee JH, et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol 2010;33:370\u2013375","journal-title":"Am J Clin Oncol"},{"key":"9799_CR564","doi-asserted-by":"crossref","unstructured":"Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies\u2013mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006;66:1152\u20131158","DOI":"10.1016\/j.ijrobp.2006.06.015"},{"key":"9799_CR565","doi-asserted-by":"crossref","unstructured":"Voroney JP, Brock KK, Eccles C, Haider M, Dawson LA. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. Int J Radiat Oncol Biol Phys 2006;66:780\u2013791","DOI":"10.1016\/j.ijrobp.2006.05.035"},{"key":"9799_CR566","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/jjco\/hyi236","volume":"36","author":"BO Choi","year":"2006","unstructured":"Choi BO, Jang HS, Kang KM, Lee SW, Kang YN, Chai GY, et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 2006;36:154\u2013158","journal-title":"Jpn J Clin Oncol"},{"key":"9799_CR567","doi-asserted-by":"crossref","unstructured":"Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, Shim JH, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One 2013;8:e79854","DOI":"10.1371\/journal.pone.0079854"},{"key":"9799_CR568","doi-asserted-by":"crossref","unstructured":"Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:372\u2013379","DOI":"10.1111\/jgh.12350"},{"key":"9799_CR569","doi-asserted-by":"crossref","unstructured":"Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 2016;122:2041\u20132049","DOI":"10.1002\/cncr.30008"},{"key":"9799_CR570","doi-asserted-by":"crossref","unstructured":"Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005;11:3799\u20133805","DOI":"10.1158\/1078-0432.CCR-04-1350"},{"key":"9799_CR571","doi-asserted-by":"crossref","unstructured":"Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;76:460\u2013466","DOI":"10.1016\/j.ijrobp.2009.02.030"},{"key":"9799_CR572","doi-asserted-by":"crossref","unstructured":"Hata M, Tokuuye K, Sugahara S, Kagei K, Igaki H, Hashimoto T, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2005;104:794\u2013801","DOI":"10.1002\/cncr.21237"},{"key":"9799_CR573","doi-asserted-by":"crossref","unstructured":"Abe T, Saitoh J, Kobayashi D, Shibuya K, Koyama Y, Shimada H, et al. Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. Radiat Oncol 2015;10:187","DOI":"10.1186\/s13014-015-0491-8"},{"key":"9799_CR574","doi-asserted-by":"crossref","unstructured":"Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653\u20131663","DOI":"10.1002\/cncr.21811"},{"key":"9799_CR575","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835\u2013844","journal-title":"Nat Rev Drug Discov"},{"key":"9799_CR576","doi-asserted-by":"crossref","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378\u2013390","DOI":"10.1056\/NEJMoa0708857"},{"key":"9799_CR577","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25\u201334","journal-title":"Lancet Oncol"},{"key":"9799_CR578","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","volume":"68","author":"R Lencioni","year":"2014","unstructured":"Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and Of its treatment with sorafenib): second interim analysis. Int J Clin Pract 2014;68:609\u2013617","journal-title":"Int J Clin Pract"},{"key":"9799_CR579","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1365-2036.2011.04860.x","volume":"34","author":"A Hollebecque","year":"2011","unstructured":"Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011;34:1193\u20131201","journal-title":"Aliment Pharmacol Ther"},{"key":"9799_CR580","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mds343","volume":"24","author":"T Pressiani","year":"2013","unstructured":"Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013;24:406\u2013411","journal-title":"Ann Oncol"},{"key":"9799_CR581","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-015-0237-3","volume":"33","author":"S Ogasawara","year":"2015","unstructured":"Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015;33:729\u2013739","journal-title":"Invest New Drugs"},{"key":"9799_CR582","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00280-011-1616-x","volume":"68","author":"JE Kim","year":"2011","unstructured":"Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011;68:1285\u20131290","journal-title":"Cancer Chemother Pharmacol"},{"key":"9799_CR583","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/jgh.12310","volume":"28","author":"HY Kim","year":"2013","unstructured":"Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:1756\u20131761","journal-title":"J Gastroenterol Hepatol"},{"key":"9799_CR584","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"14","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;14:217\u2013231","journal-title":"J Hepatol"},{"key":"9799_CR585","doi-asserted-by":"crossref","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245\u2013255","DOI":"10.1002\/ijc.25864"},{"key":"9799_CR586","doi-asserted-by":"crossref","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56\u201366","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"9799_CR587","doi-asserted-by":"crossref","unstructured":"Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, et al. Analysis of sorafenib outcome: focusing on the clinical course in patients with hepatocellular carcinoma. PLoS One 2016;11:e0161303","DOI":"10.1371\/journal.pone.0161303"},{"key":"9799_CR588","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/liv.13096","volume":"36","author":"M Kudo","year":"2016","unstructured":"Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, et al. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int 2016;36:1196\u20131205","journal-title":"Liver Int"},{"key":"9799_CR589","doi-asserted-by":"crossref","unstructured":"Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067\u20134075","DOI":"10.1200\/JCO.2012.45.8372"},{"key":"9799_CR590","doi-asserted-by":"crossref","unstructured":"Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517\u20133524","DOI":"10.1200\/JCO.2012.48.4410"},{"key":"9799_CR591","doi-asserted-by":"crossref","unstructured":"Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509\u20133516","DOI":"10.1200\/JCO.2012.47.3009"},{"key":"9799_CR592","doi-asserted-by":"crossref","unstructured":"Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33:172\u2013179","DOI":"10.1200\/JCO.2013.54.3298"},{"key":"9799_CR593","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","volume":"16","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859\u2013870","journal-title":"Lancet Oncol"},{"key":"9799_CR594","doi-asserted-by":"crossref","unstructured":"Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559\u2013566","DOI":"10.1200\/JCO.2013.53.7746"},{"key":"9799_CR595","doi-asserted-by":"crossref","unstructured":"Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57\u201367","DOI":"10.1001\/jama.2014.7189"},{"key":"9799_CR596","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","volume":"14","author":"A Santoro","year":"2013","unstructured":"Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethern JL, et al. Tivantinib for second line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55\u201363","journal-title":"Lancet Oncol"},{"key":"9799_CR597","doi-asserted-by":"crossref","unstructured":"Qin S, Lim HY, Ryoo BY, LiC, Chen W, Cheng AL. Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2016;34 (suppl; abstr 4072), 2016","DOI":"10.1200\/JCO.2016.34.15_suppl.4072"},{"key":"9799_CR598","doi-asserted-by":"crossref","unstructured":"Tanwandee T, Sukeepaisarnjaroen W, Chan SL, Choo SP, Han G, Sriuranpong V, et al. A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2016;34 (suppl; abstr 4074), 2016","DOI":"10.1200\/JCO.2016.34.15_suppl.4074"},{"key":"9799_CR599","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711\u2013723","journal-title":"N Engl J Med"},{"key":"9799_CR600","doi-asserted-by":"crossref","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443\u20132454","DOI":"10.1056\/NEJMoa1200690"},{"key":"9799_CR601","doi-asserted-by":"crossref","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123\u2013135","DOI":"10.1056\/NEJMoa1504627"},{"key":"9799_CR602","doi-asserted-by":"crossref","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521\u20132532","DOI":"10.1056\/NEJMoa1503093"},{"key":"9799_CR603","doi-asserted-by":"crossref","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018\u20132028","DOI":"10.1056\/NEJMoa1501824"},{"key":"9799_CR604","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81\u201388","journal-title":"J Hepatol"},{"key":"9799_CR605","doi-asserted-by":"crossref","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017 (Epub ahead of print)","DOI":"10.1016\/S0140-6736(17)31046-2"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-017-9799-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:06:17Z","timestamp":1719245177000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-017-9799-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":605,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["9799"],"URL":"https:\/\/doi.org\/10.1007\/s12072-017-9799-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,15]]}}}